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Characterization of Genome-Wide Binding of NUCLEAR-FACTOR I-X in
Hematopoietic Progenitor Cells
Abstract
We report that ectopic expression of Nfix in primary mouse HSPC extended their ex vivo culture from 20
to 40 days. HSPC overexpressing Nfix displayed hypersensitivity to supportive cytokines and reduced
apoptosis when subjected to cytokine deprivation compared to controls. Ectopic Nfix resulted in elevated
levels of c-Mpl transcripts and cell surface protein on primary murine HSPC as well as increased
phosphorylation of STAT5, which is known to be activated down-stream of c-MPL signaling. Blocking cMPL signaling by removal of its ligand, thrombopoietin (TPO), or addition of a c-MPL neutralizing antibody
negated the anti-apoptotic effect of Nfix overexpression on cultured HSPC. Furthermore, NFIX-FLAG was
capable of binding to and transcriptionally activating a proximal c-Mpl promoter fragment. In sum, these
data suggest that NFIX-mediated up-regulation of c-Mpl transcription can protect primitive hematopoietic
cells from stress ex vivo. Understanding the direct transcriptional targets or co-binding partners of NFIX
would provide further insight into the mechanisms HSPC employ to maintain steady-state hematopoiesis
or overcome stress hematopoiesis.
To this end, we combined global transcriptional profiling and genome-wide binding to identify direct
transcriptional targets of NFIX in Nfix+/+ and Nfix-/- HPC5 cells, a primitive multi-potent hematopoietic
cell line. We find that NFIX preferentially binds enhancer and promoter genomic regions. Integrative
analysis revealed >500 differentially expressed genes of which 58% were direct NFIX targets. Many of
these genes were downregulated in the absence of NFIX, indicating that NFIX functions primarily as a
transcriptional activator in this context. PANTHER pathway analysis implicated NFIX in the regulation of
apoptosis, myeloid cell differentiation and cell-cell adhesion. Using archived ChIP-seq data, we revealed
significant co-localization of NFIX with other well-known hematopoietic transcription factors, including
pSTAT1, RUNX1, RAD21, STAT3, ETO2, FLI1, GATA2, LYL1, LDB1 and PU.1. We showed NFIX and PU.1
together target genes regulating hematopoietic cell adhesion, cell death and differentiation in
hematopoietic cells. Our data support a model in which NFIX collaborates with PU.1 to regulate
differentiation and apoptosis in hematopoietic cells. In summary, we identified direct transcription targets
and putative co-regulatory partners of NFIX.
In sum, the work here further characterizes the complex role of the NFI family member, NFIX. We show
minor perturbations in PB lineages when transplanting NfixΔ/Δ HSPC. During secondary transplants,
NfixΔ/Δ donor chimerism was similar to controls. Also, during steady-state hematopoiesis, we did not
observe any overt phenotypes in the NfixΔ/Δ mice. We discovered that overexpressing Nfix ex vivo
imparts cells with hypersensitivity to cytokines and resistance to apoptosis. These characteristics were
due to an increase in c-MPL signaling and could be abolished if this signaling was blocked. We identified
c-Mpl as the first transcriptional target of NFIX in a hematopoietic context. Finally, we have rigorously
characterized the genome-wide binding of NFIX in a hematopoietic cell line as well as identified 291
putative transcriptional targets. This work provides more data towards illuminating the role of an NFI
family member during hematopoiesis.
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ABSTRACT

Hematopoietic stem cells (HSC) are responsible for maintaining all cells in the
hematopoietic hierarchy. During periods of stress, such as infection or exposure to
radiation, HSC can replenish the hematopoietic system. This inherent characteristic is
regularly exploited in the clinic to treat diseases such as, leukemia, lymphomas and other
non-malignant disorders. However, there are still several morbidities and mortality
associated with HSC transplant (HSCT). Several efforts have been made since the first
successful bone marrow transplant (BMT) to improve transplant outcomes. Our lab has
contributed to better understanding the molecular regulators of HSCT by identifying 18
genes required for successful HSCT. We reported the transcription factor, nuclear factor
I-X (Nfix), functions as a positive regulator of HSC biology during transplantation.
To confirm that Nfix is required for HSCT, we utilized a genetic model to
temporally delete Nfix in vivo specifically in hematopoietic cells. We found that the NfixshRNA originally used to suggest the importance of Nfix in HSCT, targets other genes in
addition to Nfix. Interrogating the need for Nfix during HSCT using our genetic model,
we found that Nfix-deficient hematopoietic stem and progenitor cells (HSPC) exhibit a
modest, but significant, increase in peripheral blood (PB) donor chimerism. Specifically,
there was a small but significant increase in donor chimerism in the lymphoid lineage but
not in the myeloid lineage. We learned these HSPC are capable of secondary transplant
and do not display a decrease in colony-forming ability, suggesting the HSC are
functionally similar to controls. During steady-state hematopoiesis, Nfix-deleted HSPC
could contribute to normal hematopoiesis and mice had normal complete blood counts
(CBC). The cells did not exhibit any perturbations in lineage distribution. Together, these
data suggest Nfix is an unessential factor during HSCT and steady-state hematopoiesis.
However, we cannot exclude the possibility of redundancy or compensation within the
NFI family. More work with double or triple NFI-knockout models is necessary to truly
interrogate these hypotheses. Nonetheless, in contrast we observed that ectopic
expression of Nfix in HSPC ex vivo results in significantly reduced apoptosis.
We report that ectopic expression of Nfix in primary mouse HSPC extended their
ex vivo culture from 20 to 40 days. HSPC overexpressing Nfix displayed hypersensitivity
to supportive cytokines and reduced apoptosis when subjected to cytokine deprivation
compared to controls. Ectopic Nfix resulted in elevated levels of c-Mpl transcripts and
cell surface protein on primary murine HSPC as well as increased phosphorylation of
STAT5, which is known to be activated down-stream of c-MPL signaling. Blocking cMPL signaling by removal of its ligand, thrombopoietin (TPO), or addition of a c-MPL
neutralizing antibody negated the anti-apoptotic effect of Nfix overexpression on cultured
HSPC. Furthermore, NFIX-FLAG was capable of binding to and transcriptionally
activating a proximal c-Mpl promoter fragment. In sum, these data suggest that NFIXmediated up-regulation of c-Mpl transcription can protect primitive hematopoietic cells
from stress ex vivo. Understanding the direct transcriptional targets or co-binding partners
of NFIX would provide further insight into the mechanisms HSPC employ to maintain
steady-state hematopoiesis or overcome stress hematopoiesis.
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To this end, we combined global transcriptional profiling and genome-wide
binding to identify direct transcriptional targets of NFIX in Nfix+/+ and Nfix-/- HPC5 cells,
a primitive multi-potent hematopoietic cell line. We find that NFIX preferentially binds
enhancer and promoter genomic regions. Integrative analysis revealed >500 differentially
expressed genes of which 58% were direct NFIX targets. Many of these genes were
downregulated in the absence of NFIX, indicating that NFIX functions primarily as a
transcriptional activator in this context. PANTHER pathway analysis implicated NFIX in
the regulation of apoptosis, myeloid cell differentiation and cell-cell adhesion. Using
archived ChIP-seq data, we revealed significant co-localization of NFIX with other wellknown hematopoietic transcription factors, including pSTAT1, RUNX1, RAD21,
STAT3, ETO2, FLI1, GATA2, LYL1, LDB1 and PU.1. We showed NFIX and PU.1
together target genes regulating hematopoietic cell adhesion, cell death and
differentiation in hematopoietic cells. Our data support a model in which NFIX
collaborates with PU.1 to regulate differentiation and apoptosis in hematopoietic cells. In
summary, we identified direct transcription targets and putative co-regulatory partners of
NFIX.
In sum, the work here further characterizes the complex role of the NFI family
member, NFIX. We show minor perturbations in PB lineages when transplanting NfixΔ/Δ
HSPC. During secondary transplants, NfixΔ/Δ donor chimerism was similar to controls.
Also, during steady-state hematopoiesis, we did not observe any overt phenotypes in the
NfixΔ/Δ mice. We discovered that overexpressing Nfix ex vivo imparts cells with
hypersensitivity to cytokines and resistance to apoptosis. These characteristics were due
to an increase in c-MPL signaling and could be abolished if this signaling was blocked.
We identified c-Mpl as the first transcriptional target of NFIX in a hematopoietic context.
Finally, we have rigorously characterized the genome-wide binding of NFIX in a
hematopoietic cell line as well as identified 291 putative transcriptional targets. This
work provides more data towards illuminating the role of an NFI family member during
hematopoiesis.
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CHAPTER 1.

INTRODUCTION1

The Race to Define the Source of Hematopoietic Regeneration: What Are
Hematopoietic Stem Cells?

Early Studies of Hematopoiesis
The possible existence of hematopoietic stem cells (HSC) had been entertained as
early as 1896 by Artur Pappenheim who proposed a precursor cell capable of giving rise
to red and white blood cells (Figure 1-1) [1]. Pappenheim had been inspired by previous
work done in the field of embryology, leading him to the concept of stem cells. In 1906,
Alexander Maximow proposed the monophyletic theory of hematopoiesis, suggesting all
blood cells from each lineage were derived from a single precursor. He also suggested
stem cells were influenced by the marrow stroma [2]. Through the rest of the early 20th
century, research was devoted to better understanding stem cells during development,
anemia and leukemia. In 1945, Ray Owen published a paper explaining how twin cattle
could share identical blood types [3]. He postulated that the factual explanation was the
existence of an “embryonal cell ancestral to erythrocytes” that could lodge in the bone
marrow of their twin and go on to supply blood distinct from the host. Owen’s paper was
published about six weeks after the end of World War II.
Conservative estimates report over 200,000 people were killed in the nuclear blast
created by the United States in 1945 during World War II. At this time, there was
increased interest in determining how to protect humans from unintended nuclear
radiation. Jacobson et al. described their observations when the spleens of lethally
irradiated mice were shielded [4]. Here they show increased erythropoiesis and
myelopoiesis at the expense of lymphopoiesis. They concluded there may be a factor or
factors that contribute to the rapid acceleration of erythropoiesis from the spleen.
Jacobson follows this article with a thorough review making a case for a humoral factor.
He highlighted work describing enhanced recovery of hematopoiesis when: normal
spleens were transplanted to irradiated recipient mice, mashed mouse embryos were
injected intraperitoneally into irradiated mice, irradiated mice were joined with nonirradiated littermates via parabiosis or when intravenous injection of homologous bone
marrow into irradiated mice was performed [5]. Interestingly, Jacobson only speculates
that the injected cells may produce a factor (or factors) that significantly enhance
hematopoiesis after radiation injury.
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Figure 1-1. Early depiction of the hematopoietic hierarchy.
Artur Pappenheim’s 1905 drawing of the hematopoietic tree detailing the origination of
all blood cells at “1”.
Reprinted with permission from Elsevier. Ramalho-Santos M, Willenbring H. On the
origin of the term "stem cell". Cell Stem Cell 2007;1(1):35-8 doi:
http://dx.doi.org/10.1016/j.stem.2007.05.013
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Discoveries of the 1950s and 1960s Characterizing HSC
Four years later in 1956, two groups, Ford et al. and Nowell et al., presented
evidence of bone marrow chimeras after transplanting donor bone marrow into irradiated
recipients [6] [7]. Ford et al. used a distinct chromosome found in donor mice to show
chimerism in lethally irradiated recipient mice [6]. His group showed that the donor cells
persisted for more than 30 days, suggesting these cells become residents of the host bone
marrow and replicate to give rise to new blood cells. Nowell et al. used the dichotomy of
alkaline phosphatase staining found in rat and mouse bone marrow cells [7]. Mouse bone
marrow cells stained negative for alkaline phosphatase while rat bone marrow cells were
strongly positive. With elegant controls, they show that bone marrow from irradiated
mice injected with mouse bone marrow stained negative for alkaline phosphatase. On the
other hand, bone marrow from irradiated mice injected with rat bone marrow reacted
strongly to alkaline phosphatase staining. These works showed that cells are, in part,
necessary for hematopoietic recovery post-irradiation. Finally, in 1959, Miya et al.
reported that cell-free extracts prepared from spleens do not protect irradiated murine
recipients from bone marrow failure, solidifying that recovery is not singularly dependent
on a humoral factor [8].
James E. Till and Ernest A. McCulloch are credited for rigorously characterizing
HSC through the 1960s. The two described an experiment that is now the gold standard
for quantifying viable, self-renewing HSC by essentially transplanting dilutions of bone
marrow into lethally irradiated mice [9]. They found the number of macroscopic nodules
or colonies that appeared on the spleen was proportional to the number of injected bone
marrow cells. Using a distinct chromosome marker in 1963, Becker et al. described the
clonal nature of spleen nodules that formed when irradiated mice were injected with bone
marrow [10]. These data together allowed them to propose that a single cell from the
bone marrow, a “colony-forming cell”, could give rise to many differentiated cells within
a single spleen nodule. These nodules became known as spleen colony-forming units
(CFU-S) (Figure 1-2). Later the following year, Till and McCulloch tried to quantify the
number of stem cells from the bone marrow by performing serial transplants from these
CFU-S [11]. Here, their work described the self-renewal ability and multi-lineage
differentiation capacity of these colony-forming cells, which we now know are
hematopoietic stem and progenitor cells (HSPC). They also described the stochastic
nature of self-renewal and differentiation [12]. Till et al. used these data to show that the
colony-forming cells, or HSPC, do not have an unlimited capacity for self-renewal. They
showed that with repeated transplantations, eventually these cells become exhausted and
self-renewal ability is lost. They also reasoned that the progeny of these colony-forming
cells, which also have some self-renewing abilities, must not be identical to their parent
colony-forming cell as the progeny have reduced self-renewing abilities. Till and
McCulloch also worked with a group who characterized mutant mouse models [13 14].
Russell et al. showed that mice with the genetic mutation W/Wv were anemic at steady
state, significantly more sensitive to irradiation and the W/Wv HSPC had significantly
reduced colony-forming ability when transplanted but that this condition could be cured
by transplantation of isologous bone marrow from wild- type (w/w) littermates. Another
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Figure 1-2. Experimental schematic for spleen colony-forming assay.
Bone marrow would be collected from a donor mouse and injected intravenously into a
heavily irradiated recipient mouse [12]. Ten days after injection, the spleen from the
recipient mouse would be isolated and observed for nodules. These nodules consisted of
clones of differentiated cells from a single colony-forming cell.
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model, the S1/S1d mouse model had a similar phenotype as the W/Wv model, except w/w
bone marrow transplantation could not rescue the anemia. These two groups coordinated
together and reasoned that in the W/Wv model there was a cell-intrinsic defect, resulting in
anemia and reduced colony forming activity after transplantation. Conversely, in the
S1/S1d model, a cell-extrinsic signal must be compromised during transplantation. In a
paper published in 1965, McCulloch et al. showed that when bone marrow from S1/S1d
mice was transplanted into W/Wv mice, erythropoiesis was restored [15]. For much of
their careers, Till and McCulloch remained focused on understanding HSC kinetics and
dissecting how the stem cells balanced self-renewal, an explosive proliferative capacity
and differentiation. Concurrently, the field of bone marrow transplant in humans was
garnering success. The first successful bone marrow transplant was conducted in 1956,
and by the 1960s, donor selection was improved by identifying the necessity for human
leukocyte antigen (HLA) matching between donors and recipients.

Hematopoietic Stem Cell Transplant as Treatment for Hematopoietic Malignancy
and Disease
The Nobel Prize in Physiology and Medicine was awarded to E. Donnall Thomas
in 1990 for his discoveries concerning organ and cell transplantation to treat human
disease, and thus is recognized as the “Father of bone marrow transplantation” . Thomas’
first attempts of allogeneic bone marrow transplant with humans began in 1957 [16].
These six transplants did not yield life-long maintenance of the hematopoietic system but
were the starting point for Thomas’ career in improving BM transplants. Studies in 1958
by Uphoff and Law revealed that donor histocompatibility genes (H-1, H-2, H-3), coding
for antigens that would be present on the surface of cells, deserved important
consideration for successful allogeneic transplants in mice [17]. In this work, differences
especially in the H-2 phenotype between donors and recipients resulted in significant loss
of transplanted grafts and overall reduced survival, supporting the concept of an immune
response elicited by donor marrow. Thomas conducted an experiment where he showed
lethally irradiated canines could be reconstituted with bone marrow from littermates but
failed to survive due to infection and other issues, otherwise known as secondary
syndromes [18]. Thomas successfully transplanted bone marrow from two sets of
identical twins in 1959 to treat leukemia (Figure 1-3) [19]. Through the 1960s Thomas
continued BM transplant experimentation in canines. Thomas recognized the importance
of radiation dosage resulting in the destruction of the host’s immunologic defense
allowing a graft to be transplanted successfully [18] as well as administration of the
immunosuppressive drug, Methotrexate [20 21]. He also worked on improving the
procurement and storage of marrow cells [22 23]. In 1968, Storb et al. dramatically
improved allogeneic transplantation in canines by including histocompatibility assays in
donor selection [24 25], something that had been shown previously in mice [17 26]. Later
these assays would be known as HLA matching. By December 1968, two groups had
reported case studies where patients with immunological disorders (i.e. Wiskott-Aldrich
syndrome and X-linked severe combined immunodeficiency) could be transplanted with
bone marrow from histocompatibility-gene matched siblings, effectively curing the

5

Figure 1-3. A timeline of the history of bone marrow transplantation.
Reproduced with permission from Appelbaum, F. R. (2007). “Hematopoietic-cell transplantation at 50”. New England Journal of
Medicine, 357(15), 1472. Copyright Massachusetts Medical Society.
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this time, allogeneic transplantation rapidly expanded as a treatment option for many
malignancies and disorders.

Indications for HSCT and Complications
The previous two decades have witnessed an increased trend in survival of people
diagnosed with hematopoietic diseases and treated with HSCT [27]. Figure 1-4 indicates,
leukemia and myelodysplastic syndromes (MDS) are the most common indications for
allogeneic HSCT, in addition to aplastic anemia (AA) and other non-malignant diseases.
Autologous HSCT is more commonly used to treat lymphomas and myelomas, as well as
other cancers (i.e. Breast cancer, germ cell tumors, etc.) (Figure 1-4). HSCT patients are
normally treated with a preparative or conditioning regimen consisting of high doses of
chemotherapy or radiotherapy and immunosuppressive drugs. There is ongoing work
trying to improve these regimens by reducing toxicities and dampening acute adverse
effects. However, there are still many complications associated with HSCT, such as
engraftment failure, infection and mortality (Figure 1-5). For example, graft-versus-host
disease (GVHD) is a common obstacle encountered by recipients of allogeneic HSCT.
GVHD can be classified as either acute (aGVHD) or chronic (cGVHD), based on the
amount of time between HSCT and disease presentation, organ involvement, and other
histological analyses [28]. GVHD develops when donor derived T-cells identify recipient
cells as foreign and an immune response is mounted against the host. This disease is
associated with impaired hematopoiesis and poor prognosis. The precise mechanism for
how GVHD adversely affects BM recovery is still being explored. Knowledge of the
regulatory mechanisms of HSC is highly complex and made more complicated by the
surrounding microenvironment.

Extrinsic and Intrinsic Factors Necessary for Successful HSCT

Bone Marrow Reconstituting Niche
As mentioned previously, the first successful human BM transplant was reported
in 1959, and by the 1960s, donor selection was improved by identifying the necessity for
HLA matching between donors and recipients. In 1984, it was established that human
HSC expressed the surface antigen CD34 [29 30]. Shortly after, CD34+ cells were shown
to repopulate irradiated baboons [31]. Finally, transplantation protocols were drastically
transformed by the discovery that recombinant human granulocyte-macrophage colony
stimulating factor (rhGM-CSF) and recombinant human granulocyte-colony stimulating
factor (rhG-CSF) could mobilize and enhance the number of CD34+ HSC collected from
a patient’s blood [32]. Mobilized peripheral blood stem cells are now the most commonly
used source of HSC for transplantation [27]. In 2018, over 14,000 autologous HSCT and
over 9,000 allogeneic HSCT were performed in the United States to treat hematologic
disease; the vast majority of stem cells being isolated by means of mobilization. Several
distinct strategies have been implemented to induce PB mobilization of HSC for
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Figure 1-4. Indications for HCT in the United States as of 2018.
Most transplants conducted involve the patient’s own marrow (autologous) and are used
to treat myeloma, non-Hodgkins lymphomas (NHL) and Hodgkins disease (HD). Acute
leukemias (AML, ALL) and MDS (combined with MPNs) are the most common
indications for allogeneic transplants accounting for 75% of allogeneic HCTs.
Reprinted with permission from D'Souza, A, Fretham C, Lee SJ, et al. Current Use of and
Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow
Transplant. 2020 May 11:S1083-8791(20)30225-1, doi: 10.1016/j.bbmt.2020.04.013,
PMID 3243804. https://pubmed.ncbi.nlm.nih.gov/32438042/ .
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Figure 1-5. Causes of death after HCT.
(A) Causes of death after autologous HCT. (B) Causes of death after HLA-matched
sibling HCT. (C) Causes of death after unrelated donor HCT. These data represent 3-year
mortality and conducted in 2016-2017.
Reprinted with permission from D'Souza, A, Fretham C, Lee SJ, et al. Current Use of and
Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow
Transplant. 2020 May 11:S1083-8791(20)30225-1, doi: 10.1016/j.bbmt.2020.04.013,
PMID 3243804. https://pubmed.ncbi.nlm.nih.gov/32438042/.
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transplantation. The most commonly used HSC mobilizer is G-CSF (filgrastim). During
homeostasis, serum G-CSF protein levels in healthy individuals are relatively low and
produced primarily by macrophages and monocytes [33]. However, during challenge,
such as bacterial infections or cytotoxic therapies, the BM endothelium and fibroblasts
are induced to produce G-CSF [34]. In the niche, administered rhG-CSF can significantly
increase numbers of neutrophils, which release proteolytic enzymes that cleave adhesion
molecules bonding HSC to its BM niche and thereby mobilize HSC to the periphery.
Fundamentally, all HSC mobilization strategies depend on disrupting HSC engagement
with its homeostatic niche (i.e., h-niche) in the BM.
The BM HSC niche, as a hypothesis, was first proposed by Raymond Schofield
about 20 years after the first successful BM transplant [35]. He suggested that HSC are
juxtaposed with other cells that guide HSC self-renewal, asymmetric division and
quiescence. This hypothesis is now well supported as many distinct cell types are now
known to support the HSC niche (both directly and indirectly) including macrophages,
endothelial cells, sympathetic nerve cells, adipocytes, megakaryocytes, osteolineage
cells, mesenchymal stem cells (MSC), and neutrophils (reviewed in [36]). Secreted
factors and the extracellular matrix (ECM) also contribute to the regulation of the niche
and HSC. Although significant advances have been made in the mobilization and
collection of HSC for transplant, the challenge still remains that very few transplanted
HSC actually participate in the stable engraftment and reconstitution of patients [37 38].
Thus, strategies focused on improving the efficiency of HSC engraftment could
significantly reduce both the number of HSC required for transplant and transplant
morbidity by allowing for milder conditioning regimens. Developing these strategies
requires a deep understanding of the cell autonomous and non-cell autonomous
mechanisms influencing the successful engagement of HSC with the BM niche.
Transplanted HSC must overcome multiple bottlenecks during transplantation.
Paramount among these is engaging with a niche damaged by disease, myeloablative
therapy and conditioning regimens. Megakaryocytes, osteoblasts, adipocytes and
endothelial cells represent multiple examples of cellular components of the BM niche
perturbed by conditioning regimens, both directly and indirectly. Outlined in Table 1-1 is
our current understanding of the post-ablated niche, designated here as the “BM
reconstituting niche (r-niche),” and the key players involved in fostering transplanted
HSC.
BM stromal cells and secreted factors contribute to recovery of the r-niche
and hematopoiesis
Vascular regeneration is critical for successful HSC engraftment. Transplant
conditioning dramatically alters the BM microenvironment. Irradiation or
myelosuppression induces the BM vasculature to regress, become dilated, leaky, and
highly unorganized [39]. Three to seven days after lethal irradiation of mice, 20% of
endothelial cells die. For efficient BM regeneration, new construction or repair of
damaged blood vessels must occur. Extrinsic factors that promote neovascularization
after myelosuppression include vascular endothelial growth factor A (VEGFA) and
angiopoietin-1 (ANGPT-1), which are secreted by cells expressing the Leptin
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Table 1-1.
Comparison of bone marrow cell types and their function in the hniche and r-niche.
Cell type
Adipocytes

h-Niche
• Source of Adiponectin
• More common with
age and obesity
• Mouse thoracic
vertebra bone marrow
is adipocyte rich with
fewer HSC

r-Niche
• Source of SCF
• Promotes BM
recovery
• Adipose-deficient
mice have increased
BM repopulating
ability

References
[40 41]

Endothelial Cells

• Conduit for HSC
movement in and out
of marrow
• Component of
vascular niche
• Supportive scaffold for
BM stromal cells

• Damaged, leaky
• Upregulates EGF,
TIE2, G-CSF, PTN,
TN-C, VCAM1, ESELECTIN
• Promotes BM
recovery

[39 42-45]

• Critical source of
SCF, CXCL12,
ANGPT1, VEGFA
• Increased proliferation
post-irradiation
• Promotes BM
recovery

[40 42]

[46]

Leptin Receptor+ • Source of SCF,
MSC
CXCL12, ANGPT1
• Regulates HSC
maintenance
• Located near sinusoids

Macrophages

• Source of CXCL12
• Depletion leads to
HSC mobilization
• Regulates Nestinþ
MSC gene expression

• Proposed signaling
axis with NPY
• NPY-induced elevated
Tgfb expression
• Promotes BM
recovery

Megakaryocytes

• Source of platelets
• Source of TPO
• Perivascular

• Relocate to endosteum [47]
• Upregulate PDGFb,
PDGFBB, bFGF
• Promotes BM
recovery
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Table 1-1.

Continued.

Cell type
Nestin+ MSC

h-Niche
• Source of ANGPT1,
CXCL12
• Regulates HSC
maintenance and
retention

r-Niche
• CXCL12 supports BM
recovery

References
[36 42 48]

Osteolineage
Cells

• Maintenance of bone
• Source of CXCL12
• Component of
endosteal niche

• Multi-layered
• Upregulates CXCL12,
IL-18, EMBIGIN, ANG
• Primary site of HSC
homing
• Promotes BM recovery

[49-51]

Sympathetic
Nerve Fibers

• Source of TGF-β
• Regulates HSC
quiescence and
maintenance

• Upregulates NPY,
β-adrenergic signaling
• Promotes regeneration
of endothelium and
Nestin+ cells
• Promotes BM recovery

[46 52 53]

Source: Reprinted with permission. Walker M, McKinney-Freeman S. Adult
Hematopoietic Stem Cell Engagement with the Myeloablated Bone Marrow Niche. In:
Reis RL, ed. Encyclopedia of Tissue Engineering and Regenerative Medicine. Oxford:
Academic Press, 2019:221-27.
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receptor (LepR) and HSPC, respectively [40]. LepR+ cells are a sub-population of MSC
with multipotent potential and are critical for HSC maintenance in the h- and r-niche [40
42 48]. Regenerating BM endothelial cells upregulate expression of the ANGPT-1
receptor, epidermal growth factor homology domains-2 (also known as TIE2). When
ANGPT-1/TIE2 signaling is disrupted, regeneration of BM endothelial cells is delayed,
resulting in a concomitant delay in HSC reconstitution. Other factors secreted by
endothelial cells are also increased shortly after myelosuppression, including epidermal
growth factor (EGF) and EGF receptor agonist, AMPHIREGULIN [54]. In mice,
systemic addition of EGF represses PUMA-mediated apoptosis in HSC resulting in
increased HSC survival and BM regeneration [43 45]. Further, conditional deletion of
Jagged-1, a NOTCH ligand, specifically in endothelial cells results in impaired HSC
regeneration after lethal irradiation [55]. Although the NOTCH-pathway appears
dispensable for normal hematopoiesis, JAG1-signaling via NOTCH in BM endothelial
cells is necessary for efficient hematopoietic regeneration. Another BM endothelial
secreted factor of interest is pleiotropin (PTN). PTN administration increases mouse
survival after lethal irradiation and HSC transplantation via induction of RAS/MEK/ERK
signaling, which promotes HSC quiescence [56]. PTN also regulates HSC homing and
retention post-irradiation. In summary, VEGFA, ANGPT-1, EGF, and JAG1 are all
upregulated by endothelial cells, promoting BM recovery (Figure 1-6). The vasculature
is the conduit for transplanted HSPC to travel to the BM or from the BM to the periphery
during mobilization or inflammation. Recovery of the vasculature is one of the first
critical steps in successful HSC engraftment. Our further understanding of how
endothelial cells mechanistically regulate HSPC function and how we can lessen the
collateral damage inflicted on vasculature will facilitate efforts to improve mobilization
and engraftment.
Mesenchymal stem and progenitor cells maintain HSC during homeostasis and
BM regeneration. Interestingly, some BM niche cells tolerate radiation better than
others. MSC are more resistant to radiation-induced ablation than HSC [57]. MSC are a
subset of multipotent progenitors that give rise to non-hematopoietic cells in the BM,
especially during regeneration. The LepR marks MSC capable of generating bone,
adipocytes, and cartilage in culture and after transplantation. Although LepR+ cells are
essential for maintaining HSC in the h-niche, less is known about their role during stress
or after myeloablation [48]. Recent evidence suggests that they also support HSCs in the
r-niche. For example, after irradiation, LepR+ MSC are the main source of new BM
osteoprogenitors and adipocytes, which are required to coordinately support blood
regeneration in the r-niche after HSCT [40]. Both during homeostasis and after HSCT,
LepR+ cells are a critical source of stem cell factor (SCF) and C-X-C motif chemokine
ligand 12 (CXCL12). SCF is key supportive cytokine of HSC in the niche and CXCL12,
with its receptor C-X-C chemokine receptor type 4 (CXCR4), is a master regulator of
HSC migration and survival. Although many cell types in the BM produce SCF (e.g.,
endothelial cells, osteolineage cells, adipocytes, LepR+ cells, and HSPC), only LepR+
cell-derived SCF is critical for HSC reconstitution post-transplant . Overall, MSC are
essential for HSC reconstitution in the r-niche, where they function as a key source of
multiple critical supportive secreted factors (e.g., SCF and CXCL12) and differentiate
into osteoprogenitors and adipocytes (Figure 1-6). There is currently great interest in
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Figure 1-6. Proposed bone marrow reconstituting niche recovering from irradiation.
Endothelial cells are damaged and vessels become leaky (no distinction between arterioles and sinusoids have been made). Some
endothelial cells succumb to irradiation-induced apoptosis. Surviving endothelial upregulate synthesis of TIE2, G-CSF, PTN, and
EGF. The endosteal niche has become multi-layered and radio-resistant megakaryocytes have relocated from the vasculature to near
the endosteum, where they secrete ECM proteins and upregulate osteoblast growth-promoting factors (PDGFβ, PDGFBB, bFGF).
Sympathetic nerve fibers are damaged post-irradiation. LepR+ MSC cells secrete survival factors (depicted by ↑) and differentiate
(shown as a bold arrow) into adipocytes and osteoprogenitors. DKK1 secreted by osteoprogenitor cells acts on (shown as an arrow)
HSPC, reducing ROS, apoptosis, and senescence (depicted by ↓).
Reprinted with permission. Walker M, McKinney-Freeman S. Adult Hematopoietic Stem Cell Engagement with the Myeloablated
Bone Marrow Niche. In: Reis RL, ed. Encyclopedia of Tissue Engineering and Regenerative Medicine. Oxford: Academic Press,
2019:221-27.
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exploiting MSC clinically in regenerative therapies. They have been shown capable of
repairing damaged cardiac tissue and bone defects [58]. In the future, it will be interesting
to unravel the full multipotent potential of MSC in repairing the r-niche.
Osteolineage cells and many secreted factors aid in BM recovery posttransplant. Irradiation results in a dramatic expansion of endosteal osteoblasts,
transforming them from a single cell layer to many cell layers [59]. This expansion is
accompanied by increased secretion of CXCL12 by osteoblasts, which perturbs the
localization of BM megakaryocytes from perivascular BM to the endosteal bone surface.
Megakaryocytes may then encourage further osteoblast proliferation by secreting growth
factors like platelet-derived growth factor β (PDGF-β), PDGF-BB and basic-fibroblast
growth factor (bFGF). CXCL12 promotes megakaryocyte homing and survival [47].
During homeostasis, megakaryocytes respond to endothelial-derived CXCL12 and
protrude into the vessels to release platelets directly into the bloodstream. Vascular
damage caused by irradiation contributes to thrombocytopenia in patients by disrupting
these endothelial-associated megakaryocytes. Administration of TPO in combination
with CXCL12 expands megakaryocytes and increases platelets in irradiated mice [60].
TPO regulates the DNA-damage response in HSC post-irradiation and pre-treatment
improves engraftment. These data implicate secreted factors, TPO and CXCL12, as
tantalizing targets for improving outcomes in patients undergoing HSCT. In 2008, a
nonpeptide TPO receptor agonist, eltrombopag, was approved by the FDA for treatment
of chronic immune (idiopathic) thrombocytopenic purpura. In a small case study,
eltrombopag was used to treat prolonged thrombocytopenia in patients who had received
HSCT [61 62]. This treatment resulted in platelet recovery and negated the need for
platelet transfusion. Osteoprogenitor cells also secrete the WNT inhibitor, Dipkkof-1
(DKK1) [63]. DKK1 promotes increased recovery of HSC numbers after irradiation,
while its deletion results in reduced HSPC numbers after irradiation. Thus, BM
osteoprogenitors are a critical source of DKK1. Mechanistically, DKK1 reduces
mitochondrial reactive oxygen species (ROS), decreasing apoptosis and senescence in
HSPC. DKK1 can also induce secretion of EGF from BM endothelial cells, which further
aids in HSC recovery post-transplant [64]. Several novel secreted factors were recently
discovered that are expressed by osteolineage cells residing close to transplanted HSPC
[50]. Three of these, including the proinflammatory cytokine IL-18, the cell adhesion
molecule EMBIGIN, and the secreted RNase ANGIOGENIN (ANG) have been found to
play a key role in regulating HSC in both the h-niche and r-niche. ANG expression in the
r-niche is required for efficient HSC transplantation [65]. Further, HSC transplanted into
mice that lack ANG display compromised serial transplantation activity. Therefore, ANG
likely functions as a non-cell autonomous factor that regulates HSC quiescence and selfrenew in the h-niche. IL-18 appears to act specifically on short-term reconstituting HSC,
thus enhancing acute hematopoietic repopulation post-transplant [50]. EMBIGIN
regulates HSPC quiescence and homing post-transplant. HSPC transplanted into
EMBIGIN-deficient mice display increased proliferation. Interestingly, osteolineage cells
expressing vascular cell adhesion molecule-1 (VCAM1) and EMBIGIN (termed VE
cells) respond to myeloablation by upregulating the expression of CXCL12, VCAM1 and
cell–cell adhesion genes. These findings implicate VE cells as a novel population whose
response to conditioning may actually be critical in supporting the stable engraftment of
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transplanted HSPC. Indeed, osteolineage cells appear to form prime real estate for
transplanted HSC via their production of multiple factors that improve HSC survival and
proliferation, such as CXCL12, DKK1, IL-18, EMBIGIN, and ANG (Figure 1-6). More
work is needed to determine if these observations can be exploited to improve
engraftment in the clinic.
The nervous system promotes regeneration of other important niche cells:
endothelium and nestin+ cells. The sympathetic nervous system (SNS) also plays a
significant role in promoting hematopoietic regeneration after myeloablation. Indeed,
chemotherapies that damage nerves also compromise hematopoietic regeneration while
protection of sympathetic nerve fibers from apoptosis via Trp53 deletion or induced
neuroregeneration via 4-methylcatechol or glial-derived neurotrophic factor treatment
promotes hematopoietic regeneration [66]. The SNS appears to promote hematopoietic
regeneration indirectly by activating β-adrenergic signaling and secreting neuropeptides
in the niche. Denervation of the BM or blocking adrenergic signaling results in an
increased loss of BM endothelial and Nestinþ mesenchymal cells following
myeloablation, which stifles hematopoietic regeneration. Nestin+ cells are key sources of
CXCL12 during homeostasis to which HSC home after lethal irradiation and transplant.
Nestin+ cells crosstalk with macrophages in the h-niche and maintain HSC retention. In
vitro, macrophages respond to Neuropeptide Y (NPY), a secreted neurotransmitter from
sympathetic nerves, via the NPY receptor, Y1 [67]. Evidence suggests NPY, acting via
the macrophage Y1 receptor, induces release of transforming growth factor β (Tgf-β) to
suppress HSC cell cycling; preventing premature exhaustion. Whether these findings
translate in vivo is unclear. Indeed, NPY treatment reduces irradiation-induced nerve
damage and improves engraftment. HSC cannot efficiently engraft the BM of mice
lacking NPY due to reduced homing and increased apoptosis in both stromal populations
and HSC themselves [68]. Thus, NPY is a critical regulator of HSC during homeostasis
and regeneration, making it ripe for clinical exploitation to improve outcomes in patients.
A better understanding of how the nervous system regulates HSC is likely to illuminate
additional factors that could be exploited to improve HSC engraftment and BM recovery.
In sum, β-adrenergic signaling and NPY are key SNS-derived players that regulate the rniche.
Bone morphogenic proteins negatively regulate HSC repopulating activity.
During homeostasis, sympathetic nerves ensheathed by nonmyelinating Schwann cells
secrete factors, such as TGF-β, that regulate HSPC cell cycle dynamics and quiescence
[52]. Multiple bone morphogenic proteins (BMP), which belong to the TGF-β family,
modulate bone mass and maintain bone homeostasis in the h-niche. Systemic infusion of
BMP7 decreases HSC expansion and engraftment [69]. In contrast, infusion of NOGGIN,
a BMP antagonist, has the opposite effect. BMP4 is critical for HSC maintenance during
homeostasis and after transplantation [70]. Interestingly, wild type (WT) HSC are
capable of multilineage reconstitution in lethally irradiated BMP4-deficient recipients.
However, HSC previously transplanted to a BMP4-deficient recipient displayed poor
repopulating activity when transplanted into secondary recipients. The critical source of
BM BMP4 post-transplant is unclear, as osteolineage cells, vascular endothelial cells,
perivascular cells, radio-resistant T-cells and megakaryocytes all produce BMP4 in
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response to radiation. BMP4 also induces BM adipogenesis in irradiated mice by
inducing up-regulation of peroxisome proliferator activated receptor-g, a key
transcriptional regulator of adipogenesis [71]. In sum, BMP4 and BMP7 negatively
regulate HSC repopulating activity; in contrast, treatment with a BMP4 antagonist
improves engraftment. The TGF-β gene family is large and has been implicated in
homeostatic regulation of HSC and other somatic stem cells. It will be interesting to see
how other family members are involved in HSC repopulating activity.
Adipocytes: a source for SCF. Adipocytes have been implicated as both negative
and positive regulators of hematopoietic regeneration [40 41]. They appear to be a key
source of BM SCF during HSC regeneration post-irradiation and deletion of SCF from
adipogenic-restricted LepR+ progenitors results in reduced HSC regeneration in mice
post-transplant. Indeed, co-transplantation of BM CD45-CD31-Sca1+CD24+ multipotent
progenitors that give rise to adipogenic progenitors and express LepR and CXCL12,
enhances HSC repopulation. However, high adipocyte content also correlates with low
HSC numbers in different BM compartments and mice with severely diminished
adipogenesis possess HSC with enhanced repopulating ability. It appears that very early
adipogenic progenitors promote HSC regeneration and function while downstream
adipogenic progenitors suppress HSC function. Relatively little is currently known about
the factors secreted by BM adipocytes (i.e., adipokines) during homeostasis and
regeneration. Adiponectin, a secreted adipokine, regulates HSC growth and HSC express
the cognate receptor. However, adiponectin is elevated in HSCT patients diagnosed with
GVHD and has antiangiogenic properties [72]; not effective in an environment requiring
vascular repair. There is controversy in the field as to whether adiponectin has pro- or
anti-inflammatory mechanisms. Chronic inflammation is associated with BM
dysfunction. Although more work is needed to resolve these conflicting results and to
clarify the role of adipocytes in the r-niche, most current evidence suggests a positive role
for BM adipocytes regulating BM repopulation. Further, given that BM adipocytes
increase with both age and obesity, as obesity rates increase and a large flux of people
enter old age, identifying the critical roles of adipocytes during homeostasis and
regeneration is paramount.
Direct cell-to-cell communication promotes HSC engraftment and BM
regeneration
Cells communicate directly with other cells via integrins, gap junctions and
adhesion molecules. Cells also interact with elements in their surrounding milieu.
Multiple components of the ECM are important for hematopoietic recovery
posttransplant (Figure 1-6 and Table 1-2). Significant cellular components of the rniche, such as megakaryocytes, upregulate fibrous ECM proteins like laminin, Type IV
collagen and fibronectin in response to myeloablation; facilitating the physical interaction
of HSC with the BM niche. Many of these proteins also promote viability and expansion
of HSC in ex vivo cultures. HSC survival post-transplant can be mediated by direct cell–
cell communication. Gap junctions are channels between cells that allow for the direct
exchange of small molecules. These channels are composed of connexins, which are
dodecamers that link together on juxtaposed cells. Connexin 43 (Cx43) is required for
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Table 1-2.
Comparison of forms of cellular communication in the bone marrow
and their function in the h-Niche and r-Niche.
Cellular communication
Connexin-43

h-Niche
• Regulates HSC
traffic to and from
BM
• Expressed by
osteolineage cells

r-Niche
• Facilitate ROS
transfer between
cells

References
[73 74]

E-Selectin

• Leukocyte rolling

• Aids in homing,
engraftment and
HSC proliferation

[44 75-77]

Junctional Adhesion
Molecules

• Involved in
immune response,
inflammation, and
leukocyte
migration

• Required for
survival and
engraftment

[78 79]

MADCAM1

• Undetermined

• Promotes
engraftment

[80]

Tenascin-C

• KO has normal
hematopoiesis
• Part of adhesion
molecule family

• Upregulated after
myeloablation
• Induces HSC
proliferation
• Regulates cell
cycle genes

[81]

VCAM1

• Regulates HSC
egress from BM

• HSC homing posttransplant

[75]

Source: Reprinted with permission. Walker M, McKinney-Freeman S. Adult
Hematopoietic Stem Cell Engagement with the Myeloablated Bone Marrow Niche. In:
Reis RL, ed. Encyclopedia of Tissue Engineering and Regenerative Medicine. Oxford:
Academic Press, 2019:221-27.
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HSC regeneration after myeloablation in mice [73]. It is expressed by both HSPC and
osteolineage cells and facilitates the transfer of ROS from HSPC to non-hematopoietic
cells in the r-niche [74]. This likely helps to diminish ROS levels, which are elevated
post-irradiation and toxic to cells. VCAM1 is expressed by endothelial cells and its
receptor, very-late-antigen 4 (VLA4, also known as α4β1), is expressed by HSPC.
Blocking VCAM1 inhibits HSPC homing to the BM [75]. Mucosal addressing cell
adhesion molecule-1 (MADCAM1, also known as α4β7) is also expressed by endothelial
cells [80]. Endothelial expression of MADCAM1 is induced by irradiation and blocking
MADCAM1 is detrimental to HSCT. Junctional adhesion molecules (JAM) are critical
regulators of the physical interaction of HSC with their niche. JAM-A, JAM-C, JAM4,
and ESAM are all expressed by HSC [79]. In contrast, JAM-B is expressed by BM
stromal cells and is required for survival and engraftment of lethally irradiated recipients
[78]. Tenascin-C (TN-C) is a non-fibrous component of the ECM. After myeloablation,
TN-C is secreted by endothelial cells and CXCL12-abundant reticular cells in the r-niche
[81]. HSPC express integrin α9, which is the ligand for TN-C. TN-C promotes HSPC
proliferation in an integrin α9- dependent manner and also increases expression of cellcycle-promoting genes while suppressing inhibitory cell cycle genes. α9 integrin
regulates HSPC–niche interactions, as do α4, α6, and β1 integrins [82-84]. While
integrins are one means of maintaining cellular interactions, cadherins and selectins also
facilitate cell–cell interactions. P-selectin and E-selectin are canonical regulators of
leukocyte rolling [76]. E-selectin, expressed on endothelial cells, aids in the homing,
engraftment, and proliferation of HSPC. E-selectin is upregulated after irradiation in mice
and E-selectin+ endothelial cells are found mostly near the endosteum, where HSPC
localize, proliferate and differentiate [77]. An E-selectin antagonist reduces HSC cycling,
increases HSC survival post-transplant and enhances neutrophil recovery in the
peripheral blood [44]. Thus, this antagonist may be an attractive clinical target for
transplant patients.
More studies are needed to further understand the roles of fibrous ECM proteins
such as, laminin, Type IV collagen and fibronectin. For example, HSC cultured on a
fibronectin scaffold display significant expansion [85]. Furthering knowledge of these
components could improve the ex vivo expansion of HSC, which will be useful during
HSCT. Additionally, Cx43 is required for ROS transfer between HSC and stromal cells.
Vascular cell adhesion molecule 1 and MADCAM1 are expressed by endothelial cells
and are essential for HSC homing and BM regeneration, respectively. Junctional
adhesion molecules, TN-C, integrins, and E-selectin are necessary for BM regeneration in
the r-niche after irradiation.

Functional Screen Identifies Regulators of Murine Hematopoietic Stem Cell
Repopulation
Successful HSCT requires that transplanted hematopoietic cells migrate to the
appropriate marrow space, engage with the r-niche, receive survival cues and proliferate
sufficiently to repopulate a recipient whose own hematopoietic system has been ablated
or compromised. Considerable effort has been directed toward understanding the bone
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marrow niche, as described previously. Our lab conducted a screen of genes as potential
molecular regulators of HSPC during transplant [86]. Genes of interest were knockeddown via shRNAs in HSPC and transplanted into lethally irradiated mice. This study
revealed 15 genes that were required for hematopoietic repopulation ability, 13 of which
not previously implicated in HSC biology. These genes include Arhgef5, Cadps2,
Crispld1, Emcn, Foxa3, Fstl1, Glis2, Gpr56, Myct1, Nbea, P2ry14, Smarca2, Sox4,
Stat4, Zfp521 and Nfix (Figure 1-7A). Genes found not be required for hematopoietic
repopulation in HPSC is included in Figure 1-7B. In general, there was a significant
decrease in the donor chimerism in the PB but overall the PB lineage distribution
remained similar to controls, except in recipients of HSPC treated with Cadps2 and
Foxa3 shRNAs (Figure 1-7C). In order to interrogate functional defects in HPSC where
each of these genes were knocked down, the colony forming ability, cell cycle status,
apoptosis and immunophenotype for each was examined. It was shown that the total
colony forming ability was only significant in HSPC treated with Arhgef5-shRNAs,
Emcn-shRNAs and Fstl1-shRNAs (Figure 1-8A, top). The distribution of the different
colonies (CFU-E, CFU-G/M/GM, CFU-GEMM) formed was significantly different from
controls in HSPC treated with Cadps2-shRNAs, Emcn-shRNAs, Fstl1-shRNAs, NbeashRNAs and p2ry14-shRNAs (Figure 1-8A, lower). HSPC treated with Argef5-shRNAs
resulted in a significant increase of cells occupying G1 and a concomitant loss of cells in
G2/S/M and G0 of the cell cycle (Figure 1-8B, top). HSPC treated with Glis2-shRNAs
had begun losing their LSK phenotype five days post-transduction compared to controls
(Figure 1-8B, middle). The only shRNAs to results in less HSPC cell death included
those targeting Glis2 (Figure 1-8C, lower). This study also identified two genes that
enhanced HSPC repopulation, Gprasp2 and Armcx1. Figure 1-8C summarizes the mean
percentage of donor chimerism in each of the cells making up the heterogeneous HSPC
population. Each of these genes are canonically associated with regulating vesicular
trafficking, cell surface receptor turnover and secretion of ECM components suggesting
active cross talk between HSPC and the niche. The work discussed here specifically
focuses on the gene Nfix.

The Nuclear Factor I Family of Site-Specific DNA Binding Proteins

Initial Discoveries of the NFI Family
The nuclear factor I (NFI) protein family was first identified in HeLa cells where
it was shown to be essential for initiating the formation of a complex between the
adenovirus (Ad) precursor terminal protein (pTP) and 5’-dCMP, the 5’-terminal
nucleotide of all human Ad DNA sequences [87]. Thus, making NFI required for Ad
DNA replication in vitro. Later, it was discovered that NFI, as well as another factor,
Oct-1, recruit Ad DNA polymerase to the origin of replication as well as the pTP via
specific recognition sites. These recognition sites were identified as a palindromic
sequence consisting of 15-16 nucleotides, TGG(N6-7)GCCA [88 89]. It was also noted
that the proteins can bind half of the consensus sequence but with lower affinity [90].
Shortly after its identification, the NFI binding sequence was observed in other virus
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Figure 1-7. shRNA-mediated knockdown of genes in HPSC identifies 15 genes
required for robust HSPC repopulating activity.
(A) Verified loss-of-function hits. A one sample Student’s t test was performed testing
the null hypothesis that the normalized measurements = 1. P-values are two-sided. §, P <
0.1; *, P < 0.05; **, P < 0.005; ***, P < 0.0001. Only p-values calculated >16 wk after
transplant are shown. (B) Functional screen non-hits. In E and F, each gene was
interrogated with at least two independent shRNAs (labeled as a, b, or c) and the
percentage of CD45.2 PB at 4 and >16 wk after transplant of recipients of gene-specific
shRNA–treated Test cells normalized to that of recipients of control shRNA–treated Test
cells is shown. (C) Distribution of T, B, and myeloid PB lineages in mCherry+CD45.2+
compartment of genes that scored as hits after retesting >16 wk after transplant. In E–G,
each bar is the average of at least four recipient mice, and error bars represent SD. In G,
asterisks denote a statistically significant difference in distribution of at least one lineage
relative to control for both shRNAs tested (P < 0.05). P-values were calculated using the
exact Wilcoxon Mann-Whitney test. ND, not determined.
Reprinted from final submission with permission from Rockefeller University Press,
Holmfeldt P, Ganuza M, Marathe H, et al. Functional screen identifies regulators of
murine hematopoietic stem cell repopulation. J Exp Med 2016;213(3):433-49 doi:
http://dx.doi.org/10.1084/jem.20150806.
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Figure 1-8. Functional analysis of HSPC treated with gene-specific shRNAs.
(A) 500 mCherry+ LSK cells transduced with control or gene-specific shRNAs were
assayed for CFU potential 5 days after transduction. Values are the mean of two to three
independent experiments normalized to control ± SE. (B) Cell cycle status of the
mCherry+ LSK cell compartment, the frequency of mCherry+ LSK cells, and apoptosis
of mCherry+ LSK cells was analyzed 5 days after transduction with control or genespecific shRNAs. Values are the mean of two to three independent experiments
normalized to control ± SE. For A and B, a one-sample Student’s t test was performed
testing the null hypothesis that the normalized measurements = 1. P-values are two-sided.
§, P < 0.1; *, P < 0.05; **, P < 0.005. (C) Heat map summarizing mean percentage of
CD45.2+ (Test cell–derived) HSC, MPP, CMP, CLP, GMP, and MEP in recipients >16
wk after transplant. Values are normalized to control recipients (i.e., 1 = yellow). Higher
chimerism relative to control = darker green; lower chimerism relative to control = darker
red. ND, not determined.
Reprinted from final submission with permission of Rockefeller University Press,
Holmfeldt P, Ganuza M, Marathe H, et al. Functional screen identifies regulators of
murine hematopoietic stem cell repopulation. J Exp Med 2016;213(3):433-49 doi:
http://dx.doi.org/10.1084/jem.20150806.
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promoters or long terminal repeats, including the mouse mammary tumor virus (MMTV)
[91] human cytomegalovirus (HCMV) [92] and the hepatitis B virus (HBV). The Ad,
MMTV, HCMV and HBV are grouped together, as each consist of double-stranded DNA
(dsDNA). There is data showing NFI proteins preferentially bind dsDNA and have very
little affinity for single stranded DNA (ssDNA) [89]. In higher eukaryotes NFI binding
sequences were identified in the promoters or regulatory regions of genes such as chicken
lysozyme [93], human IgM [94], human c-myc [95] vertebrate globin genes [96] and
mouse alpha 2(I) collagen [97]. Activation of the mouse alpha 2(I) collagen by NFI was
shown to be induced by the cytokine, TGFβ, suggesting gene regulation functions.
Eventually, there were four separate genes identified as belonging to the NFI protein
family: NFIA [98], NFIB, NFIC and NFIX [99].

NFI Family Role as Transcriptional Regulators
There is tremendous homology among the NFI family members, especially in the
amino-terminal region (Figure 1-9B, C) [100]. The amino-terminal region contains the
DNA binding and dimerization domain while the carboxy-terminal region is responsible
for controlling transcription activation or repression (Figure 1-9A). These proteins bind
as homo- or hetero-dimers [101] to regulate cellular and viral gene transcription and viral
replication. The NFI proteins bind with high affinity to the three guanine residues that are
part of the consensus sequence (TGG(N6-7)GCCA) and occur mainly at the major groove
[102]. Substitution of one of these guanine abolishes the ability for NFI to bind DNA.
The spacer region also influences the binding of NFI. Depending on the composition of
the bases, 6-7bp results in a range of binding affinity [103 104]. The NFI proteins initiate
Ad5 replication by inducing a 60 bend in the replication origin of Ad5 [105]. This bend
in the DNA was shown to depend on the presence of NFI and an A/T rich region
upstream of the NFI binding sequence. The NFI binding site has been identified in
promoters, enhancers and silencer regions of the human genome.

Expression of NFI Family Members During Development and in Adult Tissue
The NFI family is well studied in the nervous system. During mouse
embryogenesis, Nfia, Nfib and Nfix are all expressed in the developing and postnatal
brain [106]. Knockout (KO) models of Nfia and Nfib display forebrain defects, enlarged
lateral ventricles, agenesis of the corpus callosum and perinatal lethality [107-109]. The
Nfix KO model also has neurological defects and need to be kept on a soft chow diet in
order for most to avoid death at P21-P28 [110]. The NFI family members are expressed
in a variety of cell types, including multiple adult stem cell compartments [111-115].
NFIC regulates the differentiation, proliferation and apoptosis of dental follicle stem cells
[112]. Nfib is expressed by epithelial hair follicle stem cells, promoting proliferation and
differentiation [113]. Nfia functions as a transcriptional switch in multiple stem and
progenitor cell compartments. It promotes gliogenesis in the developing chick neural tube
while inhibiting further neurogenesis of ventricular zone progenitor cells [114] and
regulates the granulocytic/erythroid fate choice of human hematopoietic progenitors
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Figure 1-9. NFI domain structure, protein sequence alignment and protein
sequence homology in vertebrates.
(A) Exons are numbered 1–12. Full-length Nfib transcripts contain 12 exons, while full
length Nfia, Nfix, and Nfic transcripts contain 11 exons. The N-terminal region contains a
DNA binding and dimerization domain (bracketed and labeled DNA binding and
dimerization) and is largely encoded by exon 2. This domain contains four conserved
cysteine residues (labeled C) which are required for DNA binding and redox control.
There is also a basic alpha helical domain (bracketed and labeled alpha helix) at the start
of exon 2. The C-terminal transactivation and repression domain (labeled transactivation
and repression) is encoded from exon 3 onwards. The deduced nuclear localization
signals are labeled NLS and are at the border of exon 5 and exon 6 (colored gray). The
proline-rich region of the activation/repression domain is bracketed. (B) Homology of the
NFI family members in mouse. The predicted amino acid sequences of full length
transcripts of the NFIA, NFIB, NFIX, and NFIC family members were aligned using
Clustal W (MegAlign). The PubMed accession numbers of the messenger RNA
transcripts for NFIA, NFIB, NFIX, and NFIC used in this alignment are NM_010905,
NM_001113209, NM_001081982, and NM_008688, respectively. Conserved amino
acids between all four family members are shaded blue. NFIB has an extended Cterminus of ∼60 amino acids. (C) Percent homologies of all family members in mouse.
Analysis was performed with the aid of Clustal W, with the N-terminus arbitrarily taken
as the first 210 amino acids and the C-terminus taken as the remainder of the predicted
polypeptide. NFIA and NFIX are the most homologous, with an overall homology of
∼73%.
Reprinted with permission from Springer Nature Customer Service Centre GmbH:
Springer Nature Molecular Neurobiology Mason S, Piper M, Gronostajski RM, Richards
LJ. Nuclear factor one transcription factors in CNS development. Mol Neurobiol
2009;39:10-23.
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during in vitro differentiation [115]. The Nfi genes have been identified in almost every
organ and tissue-type (reviewed in [116]).

Nuclear Factor I-X

Nfix Is a Novel Regulator of Murine Hematopoietic Stem and Progenitor Cell
Survival
Nuclear factor I-X (Nfix) was a gene included in the functional screen described
above. In this study, shRNA-mediated knock-down of Nfix in HSPC resulted in severe
loss of repopulating ability observed as early as four weeks post-transplantation,
increased apoptosis in the HSPC compartment and reduced colony-forming ability [117].
Genes also known to promote HSPC maintenance and survival, such as c-Mpl, Mecom
and Erg, were significantly down-regulated in Nfix-deficient HSPC. Holmfeldt et al.
report data supporting a model where Nfix serves as a novel regulator of HSCT in HSPC.

NFIX Roles in Other Tissues
Nfix regulates the molecular switch from embryonic skeletal muscle to fetal
skeletal muscle
Nfix has been shown to activate fetal specific genes while repressing embryonic
specific genes, functioning as a molecular switch [118]. Messina et al. shows early Nfix
expression turns on transcription of fetal genes and reduces expression of embryonic
genes in embryonic muscle. Alternatively, preventing Nfix expression results in sustained
expression of embryonic genes in the fetus. Nfix has also been implicated in skeletal
muscle regeneration and progression of muscular dystrophies [119 120]. Interestingly,
deletion of Nfix in muscular dystrophy mouse models results in improvement of the
pathology while overexpression of Nfix exacerbates the pathology and increases muscle
regeneration.
Nfix regulates neural stem cell quiescence, proliferation and migration
Mentioned previously, the Nfi members have been well studied in the nervous
system. Nfix has been implicated in many biological functions in the brain, specifically in
neural stem cells (NSC). In quiescent NSC cultures, the NFI motif was enriched for in
enhancer regions and that NFIX is up-regulated when NSC become quiescent [121]. In
vivo, Martynoga et al. found significantly more NSC cycling in Nfix-KO brain. Another
group showed Nfix facilitates correct migration and proliferation of NSC in the mouse
brain [122]. GSEA analysis also suggests that Nfix expression in quiescent NSC may be
involved with the ECM and cell adhesion, which pairs well with Nfix regulated NSC
migration [121].
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Hypothesis and Specific Aims
The accumulated data shown by others implicates Nfix in regulating
hematopoiesis. However, the exact molecular mechanism is not understood. Our
hypothesis was that NFIX regulates the transcription of genes during steady-state and
stress hematopoiesis. In addition, we predicted genes targeted by NFIX would be
involved in cellular differentiation, apoptosis and cell adhesion. It was also expected
NFIX might cooperate with other transcription factors known to be important for
hematopoiesis. In this study, we aimed to:
•
•
•

Examine the role of Nfix during steady-state and stress hematopoiesis.
Interrogate the direct transcriptional targets of NFIX.
Investigate other key hematopoietic transcription factors that may co-occupy
regions of the genome.
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CHAPTER 2.

MATERIALS AND METHODOLOGY2

Mice and Genotyping
C57BL/6J and C57BL/6.SJL-Ptprca Pep3b/BoyJ mice were purchased from The
Jackson Laboratory (Bar Harbor, ME) and housed in a pathogen-free facility. All animal
experiments were carried out according to procedures approved by the St. Jude
Children’s Research Hospital Institutional Animal Care and Use Committee. Nfixflox/flox
mice [110] were a gift from the laboratory of Dr. Richard Gronostajski (University of
Buffalo, Buffalo). C57BL/6 HSC-Scl-Cre-ERT mice [123] were a gift from the
laboratory of Dr. Joachim Göthert (University of Duisburg-Essen, Germany). The
following genotyping primers were used to identify wild-type and mutant Nfix progeny:
(NfixF5 -5’ atggacatgtcatgggtgcgacag -3’), (NfixR1-5’ aaccagaggcacgagagcttgtc -3’),
(NfixR2 -5’ aagcccctcagctctagcacagag -3’). Polymerase chain reaction (PCR) was
completed using 1X Colorless GoTaq Flexi Buffer (Promega; Madison, WI), 2mM
MgCl2, 0.2mM dNTPs, 0.1µM NfixF5, 0.1µM NfixR1, 0.1µM NfixR2, 0.05U GoTaq
DNA Polymerase (Promega; Madison, WI) (Figure 2-1A).
The following genotyping primers were used to identify wild-type and mutant
Rosa26-Cre-ERT2 progeny: (oIMR883 -5’aaagtcgctctgagttgttat-3’), (oIMR4982 -5’
aaagtcgctctgagttgttat -3’), (oIMR316 -5’ ggagcgggagaaatggatatg-3’). Polymerase chain
reaction (PCR) was completed using 1X Colorless GoTaq Flexi Buffer (Promega;
Madison, WI), 1.5mM MgCl2, 0.2mM deoxynucleoside triphosphates (dNTPs), 2µM
oIMR883, 2µM oIMR4982, 2µM oIMR316, 0.025U GoTaq DNA Polymerase (Promega;
Madison, WI) (Figure 2-1B)
The following genotyping primers were used to identify progeny with an Slc-CreERT allele: 6E5-SCL locus (6E51-5’ aacaacaaccgggtgaagag -3’), Cre-ER[T] (CREr1-5’
atgtttagctggcccaaatg -3’). PCR was completed using 1X Colorless GoTaq Flexi Buffer
(Promega; Madison, WI), 1.6mM MgCl2, 0.2mM dNTPs, 0.2µM 6E51, 0.2µM CREr1,
0.02U GoTaq DNA Polymerase (Promega; Madison, WI) (Figure 2-1C).

Vector Construction
Mouse Nfix cDNA was purchased from GE Healthcare Dharmacon Inc.
(Lafayette, Colorado) (Accession: BC003766; Clone ID: 3491917). Nfix was cloned into
the Gateway entry vector pDONR221 (Thermo Fisher Scientific, Waltham, MA) by BP
clonase reaction, followed by transfer into pCCL-MND-U3-Gateway-PGK-GFP

2

Portions of chapter from previously published article; final submission modified with permission from
John Wiley and Sons. Hall, T.*, Walker, M.*, Ganuza, M., Holmfeldt, P., Bordas, M., Kang, G., Bi, W.,
Palmer, L.E., Finkelstein, D. and McKinney‐Freeman, S. (2018), Nfix Promotes Survival of Immature
Hematopoietic Cells via Regulation of c‐Mpl . Stem Cells, 36: 943-950. (*Co-first author). doi:
http://dx.doi.org/:10.1002/stem.2800
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Figure 2-1. Representative genotyping results.
(A) Genotyping results for the presence of the Nfix floxed alleles. Expected size for:
wild-type amplicon is 214 bp and floxed allele(s) is 420 bp. (B) Genotyping results for
the presence of the Rosa26-Cre-ERT2 knock-in allele. Expected size for: wild-type
amplicon is 320 bp and knock-in is 650 bp. (C) Genotyping results for the presence or
absence of the Scl-Cre-ERT allele. Expected size for: transgenic mutant allele is 328 bp.
L lane: 1kb plus DNA ladder, W lane: wild-type control, M lane: mutant control, N lane:
no template control.
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by LR clonase reaction to produce pCCL-MND-U3-Nfix-PGK-GFP (MND-Nfix). pCCLMND-U3-Gateway-PGK-GFP was prepared by transferring the Gateway cassette from
pRFA (Thermo Fisher Scientific) to pCCL-MND-U3-PGK-GFP downstream of the
MND-U3 promoter. pCCL-MND-U3-PGK-GFP was used as a control vector (MNDControl).

Lentivirus Production
A four plasmid system (transfer vector (i.e. Nfix), Gag/Pol, Rev/Tat, and vesicular
stomatitis virus glycoprotein G (VSV-G) envelope plasmid) was used to produce VSVG-pseudotyped lentivirus. Briefly, plasmids were co-transfected into 293T cells using
TransIT 293 (Mirus, Madison, WI) and viral supernatant was collected 48 hours
post-transfection. 293T cells were maintained in Dulbecco’s Modified Eagle Medium
(DMEM) (GE Healthcare Life Sciences, Logan, UT) supplemented with 10% fetal calf
serum (FCS) (Omega Scientific, Tarzana, CA).

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Total RNA was isolated from 70-200,000 cells after 4-7 days in ex vivo culture
using the Qiagen RNeasy Micro Kit (Qiagen, Valencia, CA), followed by reverse
transcription using the High Capacity cDNA Reverse Transcription Kit with RNase
Inhibitor (Thermo Fisher Scientific). qRT-PCR was performed on an ABI StepOnePlus
thermal cycler using SYBR Green (Thermo Fisher Scientific). Tbp was used as a
housekeeping gene, and changes in gene expression between test and control samples
were calculated using the ΔΔCt method. Primer sequences can be found in (Table 2-1)

Fluorescence-Activated Cell Sorting (FACS)
Bone marrow was harvested from the femurs, tibias, pelvic bones, and spines of
mice by crushing. c-KIT+ cells were enriched by staining the bone marrow with anticKIT microbeads (Miltenyi Biotec, San Diego, CA), followed by magnetic separation on
an autoMACS Pro Separator (Miltenyi Biotec). Following separation, cells were stained
with the following antibodies: c-KIT-APC (2B8) (eBioscience, Inc., San Diego, CA) and
SCA-1-FITC (E13-161.7) (BD Biosciences, San Jose, CA). The Lin-c-KIT+SCA-1+
(LSK) fraction was sorted on a FACSAriaIII (BD Biosciences). 4’,6-diamidino-2phenylindole (DAPI) (Thermo Fisher Scientific) was used to exclude dead cells. Gating
strategy is included in Figure 2-2.
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Table 2-1
Target
Nfix
Nfia
Nfic
c-Mpl
Bcl-xL
Erg
Gata3
Hlf
Mecom
Robo4
Tek
Tie1
Tbp

List of primers used for qRT-PCR.
Forward primer
AGGCTGACAAGGTGTGGC
GAGTCCAGGAGCAATGAGG
CCGGCATGAGAAGGACTCTAC
CTGGTCCTTCCCTGTGACT
GACAAGGAGATGCAGGTATTGG
CTAAGACAGAGATGACCGCA
CTCGGCCATTCGTACATGGAA
CCGTCTCCGAACTGTATGC
ACATGGGAGAGCAGAGATCAG
TGTGTTGCTCCTGAGGCTG
GATTTTGGATTGTCCCGAGGTCAAG
AGGAGGTGTATGTGAAGAAGAC
GAAGAACAATCCAGACTAGCAGCA

Reverse primer
CACTGGGGCGACTTGTAGAG
CCATTTCATCCTCCACAGAC
TTCTTCACCGGGGATGAGATG
GCGGTTCCTCCTCTTCACAT
TCCCGTAGAGATCCACAAAAGT
GTGGTCATATTGGGAGGCG
GGATACCTCTGCACCGTAGC
AGAACTTCCGTTTGCGAGG
TGATCATAGCAGCCAGCG
TCTGTTCACCCACTACGGTC
CACCAATATCTGGGCAAATGATGG
CCTCCAAGGCTCACTATCTC
CCTTATAGGGAACTTCACATCACAG
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Amplicon
size (bp)
103
86
187
206
124
274
134
187
151
203
306
142
129

Figure 2-2. Gating strategy for isolating HSPC.
BM cells enriched for the cell surface marker, cKit, are sorted for live, singlets and
Sca-1+ cKit+ cells, representing LSK cells (i.e. HSPC).
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Lentiviral Transduction
96-well non-tissue culture (NTC) treated plates (Thermo Fisher Scientific) were
coated with Retronectin (Takara Bio USA, Inc., Mountain View, CA) according to the
manufacturer’s instructions. After coating, lentivirus was spin loaded onto the plates for
one hour at 1000g at room temperature at 2.5×106 virus/cm2. Wells were then washed
once with phosphate buffered saline (PBS) (Thermo Fisher Scientific) and 15,000 sorted
LSK cells resuspended in 200 µL of serum-free expansion media (SFEM) (STEMCELL
Technologies Canada, Inc., Vancouver, BC) were added to each well. SFEM was
supplemented with 10 ng/mL murine stem cell factor (mSCF), 20 ng/mL murine
thrombopoietin (mTPO), human fibroblast growth factor acidic (hFGF-a) (Peprotech,
Rocky Hill, NJ), 20 ng/mL murine insulin-like growth factor 2 (mIGF-2) (R&D Systems,
Inc., Minneapolis, MN), and 5 ug/mL protamine sulfate (Sigma-Aldrich Corp., St. Louis,
MO). This cytokine combination will hereafter be referred to as “STIF.”

HSPC Ex Vivo Culture
Following 24-48 hours of lentiviral transduction, cells were washed of any
residual viral particles with PBS/2% FCS. After washing, 15,000 cells resuspended in
200 µL SFEM supplemented with STIF and 10 µg/mL heparin (Sigma-Aldrich) were
added to each well of a 96-well NTC plate. Cells were collected and passaged 1:4 into
new media every 48-72 hours. 50 µL of cells not used for passaging were simultaneously
assessed for relative growth and GFP% via flow cytometry analysis using BD
LSRFortessa (BD Biosciences) and data analysis using FlowJo (FlowJo, LLC, Ashland,
OR). To determine relative cell number, the 50 µL fraction was collected for 30 seconds
at medium speed on the same instrument for every time point assessed, and the number of
live cells collected was recorded. DAPI was used to exclude dead cells. This value was
then entered into the following equation (Equation 2-1):
relative growth = (

(live cell number × 4)
) × previous relative growth value
previous live cell number
(Eq. 2-1)

In this equation, “4” corresponds to the dilution factor of the previous passage.
For cytokine deprivation experiments, the same procedure was followed with the
exception that 25% of the normal concentrations of STIF cytokines were used.

Cytospin Preparation
Cytospins were prepared and stained using cytopads with caps (Fisher) in a 7120
Aerospray Hematology Slide Stainer/Centrifuge (Wescor, Logan, UT). Briefly, 75,000
GFP+ control or GFP+ NFIX+ cells in 100µL were centrifuged for three minutes at 1000
rpm. After letting the slides air dry, slides were stained using the Romanowsky staining
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method: eosin (Wescor), Thiazin (azure B, methylene blue) (Wescor) and light eosin
rinse (Wescor). Anhydrous methanol (Wescor) was used for fixation.

Bone Marrow Transplantation
CD45.2 “test” HSPC cells were collected and transduced with lentivirus as
described above. Twenty-four hours post-transduction, 5000 test cells were washed with
PBS and transplanted with 5000 mock-transduced CD45.1 HSPC cells into lethally
irradiated CD45.1/CD45.2 recipients. For lethal irradiation, CD45.1/CD45.2 mice
received two doses of 5.5 Gy administered three hours apart. Experimental schematic is
included in Figure 2-3.

TPO Removal and AMM2 Treatment
Ex vivo HSPC were transduced with lentivirus and plated as described above.
After 72 hours in culture, 15,000 cells were collected, washed with PBS, and replated in
200µL SFEM supplemented with 25% STIF ± TPO or ± 2 µg/mL of the c-MPL
neutralizing antibody AMM2 (Takara Bio USA). After another 72 hours in culture, cells
were collected and counted via hemacytometer, as well as analyzed for GFP%, c-KIT%,
and apoptosis via flow cytometry on a BD LSRFortessa.

Colony Forming Unit (CFU) Assays
Control and NFIX+ cells were sorted for GFP+ cells as described above and
plated in methylcellulose M3434 (STEMCELL Technologies). Colonies were scored and
counted 10-12 days after plating. For identification of CFU-Megs, sorted cells were
plated in MegaCult-C medium with collagen (STEMCELL Technologies), along with
50ng/mL TPO, 20ng/mL IL-6, and 10ng/mL IL-3. Colonies were stained and counted 6-8
days after plating, according to manufacturer’s instructions (STEMCELL Technologies).

Phosphoflow
Cells were transduced with lentivirus and plated as described above. After four to
seven days in culture, 15,000-40,000 cells were collected, washed with PBS, and replated
in 200µL SFEM without cytokines for two hours. After the incubation period, cells were
collected and treated with 20 ng/mL mTPO for 5, 10, 25, 60, or 120 minutes at 37 ºC,
followed by fixation in 1.6% formaldehyde (Avantor Performance Materials, Center
Valley, PA) for 10 minutes at room temperature. Fixed cells were then pelleted and
resuspended in ice cold methanol (Thermo Fisher Scientific), followed by 30 minutes
incubation on ice or storage at -20 ºC for later analysis. After permeabilization, cells were
washed with PBS/2% FCS and stained with fluorescent conjugated antibodies for
phosphorylation of STAT5, ERK1/2, or AKT for analysis by flow cytometry.
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Figure 2-3. Schematic of competitive transplantation with transduced CD45.2+
HSPC and mock transduced CD45.1+ HSPC.
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Luciferase Reporter Activity Assay
Constructs for luciferase reporter assays were designed by using primers listed in
Table 2-2. HindIII and XhoI restriction sites were included during primer design (bold,
lowercase in Table 2-2). Regions of the c-Mpl promoter were amplified via PCR using
these primers and fragments were purified with Wizard SV Gel and PCR Clean-up
system (Promega, Madison, WI). Purified fragments and promoterless luciferase vector
pGL4.14 (Promega) were incubated with restriction enzymes HindIII-High Fidelity and
XhoI (New England Biolabs, Ipswich, MA) and purified. Each fragment of the c-Mpl
promoter and digested pGL4.14 backbone were ligated together with T4 DNA ligase
overnight at 16C. Ligation reactions were transformed into Escherichia coli TOP10 One
Shot competent cells (Invitrogen) and plated onto LB agar plates supplemented with
100ug/mL Ampicillin. Resulting colonies were sequenced using the RVprimer3
sequencing primer. The MND-control or MND-NFIX constructs (2.5 ug) were cotransfected with pGL4.70 (hRluc) (0.125 ug) and one of the luciferase constructs
described earlier (0.875 ug) into 106 K562 cells using nucleofector kit V (Amaxa; Lonza
Group, Basel, Switzerland) according to the manufacturer’s protocol. K562 cells were
maintained in DMEM (GE Healthcare Life Sciences) supplemented with 10% FCS
(Omega Scientific). 24 hours post-transfection, cells were lysed with passive lysis buffer
and tested for reporter activity using the Dual-Luciferase Reporter Activity Assay Stopand-Glo Kit (Promega) and a BioTek Synergy H1 Multi-Mode Microplate Reader
(BioTek Instruments, Winooski, VT) according to manufacturer’s instructions.

Flow Cytometry
All flow cytometry analysis was performed on a BD LSRFortessa and all data
was analyzed by FlowJo. For determination of Lineage-SCA-1+c-KIT+ immunophenotype of ex vivo cells, the following antibodies were used: [CD3 (145-2C11), CD4
(GK1.5), CD19 (6D5), GR-1 (Rb6-8C5), TER-119 (TER-119) (BioLegend, San Diego,
CA), CD8 (53-6.7), B220 (RA3-6B2) (BD Biosciences)]-PerCP; SCA-1-PerCP-Cy5.5
(E13-161.7) (BioLegend); c-KIT-APC-eFluor780 (2B8) (eBioscience). A complete list of
antibodies used for flow cytometry is included in Table 2-3. For determination of cKIT% of ex vivo cells in the TPO and AMM2 experiments, c-KIT-PE-Cy7 (2B8)
(BioLegend) was used. For flow cytometry analysis of cell cycle, cells were collected,
washed with PBS/2% FCS, then fixed and permeabilized followed by DAPI staining. For
flow cytometry analysis of apoptosis, cells were collected, washed with PBS/2% FCS and
resuspended in Annexin Binding Buffer (BD Biosciences). Cells were then stained with
DAPI and Annexin V-APC (BD Bioscences). For phosphoflow, the following antibodies
were used: STAT5(pY694) (47); ERK1/2(pT202/pY204) (20A); AKT(pS473) (M89-61)
(BD Biosciences). For peripheral blood analysis of recipients, blood was collected from
the retro orbital plexus in heparinized capillary tubes and lysed in red blood cell lysis
buffer (Sigma-Aldrich Corp.). Cells were then stained with CD45.1-APC (A20), CD45.2v500 (104) (eBioscience), [B220 (RA3-6B2), Gr-1 (RB6-8C5), CD11b (M1/70)]-PerCPCy5.5, [B220 (RA3-6B2), CD4 (GK1.5), CD8 (53-6.7)]-PE-Cy7 (BioLegend). For
staining of megakaryocyte progenitors, cells were stained with c-KIT-APC-eFluor780
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Table 2-2.

Primer sequences used for luciferase constructs.

Sites included
-189,-127,-101,-18

Forward (5’-3’)
GGGGctcgagAATATATAC
CTCTGTGTCCCTGCC

Reverse (5’-3’)
GGGaagcttCACTGTGTGCCT
GCCTTA

-127,-101,-18

GGGGctcgagATATATACC
TCTGTGTCCCT

GGGaagcttCACTGTGTGCCT
GCCTTA

-18

GGGGctcgagGGACGTGG
GGCTGTATCTGA

GGGaagcttCACTGTGTGCCT
GCCTTA

Note: HindIII and XhoI sites are bolded and lowercase in primer sequences.

Table 2-3.

List of antibodies and respective clones used in study.
Target
CD3
CD4
CD19
Gr-1
Ter119
CD8
B220
Sca-1
cKit
Annexin V
STAT5 (pY694)
ERK1/2 (pT202/pY204)
AKT (pS473)
CD45.1
CD45.2
CD127
CD9
CD16/CD32
CD41
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Clone
145-2C11
GK1.5
6D5
Rb6-8C5
Ter-119
53-6.7
RA3-6B2
E13-161.7
2B8
47
20A
M89-61
A20
104
A7R34
KMC8
93
eBIOMWReg30

(2B8) (eBioscience), SCA-1-PE (E13-161.7) (BioLegend), CD127-PE-Cy7 (A7R34)
(Tonbo Biosciences, San Diego, CA), CD9-A647 (KMC8) (BD Biosciences),
CD32/CD16-A700 (93) (eBioscience), and CD41-PerCP-e710 (eBioMWReg30)
(eBioscience).

Chromatin Immunoprecipitation qRT-PCR
HPC5 cells were infected with lentivirus carrying MND-Nfix-FLAG or MNDcontrol constructs. 48 hours after infection, cells were sorted for GFP+ cells. GFP+ HPC5
cells were expanded to 107 in culture for no more than one week. 107 GFP+ HPC5 cells
were crosslinked with 1% formaldehyde and stored at -80C. After crosslinking, cells
were sheared and diluted. At this time, 10% of the total lysate volume was reserved as the
total input sample. Each sample received 1μg of an anti-FLAG antibody (CST, clone:
D6W5B) or rabbit IgG antibody (CST, 2729). Samples were incubated overnight at 4C
with gentle rocking. Next, Protein G Dynabeads (Fisher) were added to samples and
incubated for two hours at 4C with gentle rocking. Samples were washed with a series
of buffers and then immunoprecipitated chromatin and total input chromatin were eluted.
Chromatin were de-crosslinked and RNA and protein were digested by overnight
incubations with RNase and Proteinase K in a sodium chloride rich buffer. DNA from
ChIP samples and total input samples was extracted using phenol/chloroform. Total input
samples were diluted ten times before qPCR. The following primers were designed to
encompass NFI consensus binding sites in the Mus musculus c-Mpl proximal promoter
[Forward: cccattccccctcctctgg] and [Reverse: cctgtcagatacagccccac]. Primers used for
ChIP-qPCR were validated with serial dilutions of HPC5 genomic DNA. Total input
samples were first adjusted to represent 100% of the total chromatin present in samples.
Finally, percent input was calculated as follows (Equation 2-2):
% Input = 100 × 2(adjusted input Ct − ChIP Ct)

(Eq. 2-2)

Statistical Analysis
Statistical significance was determined using two-sample/one sample Student’s
t-tests or exact Wilcoxon rank sum tests, depending on the normality of the data as
determined by the Shapiro-Wilk test. In Chapter 4, a linear regression model was used to
examine the reduction in cell number in controls compared with NFIX+ cells. P-values
< 0.05 or < 0.1 (where indicated) were considered statistically significant in all analyses.

Cell Culture
Nfix+/+ and Nfix-/- HPC5 cells were maintained in IMDM with GlutaMax (Gibco;
Carlsbad, CA) supplemented with 5% FCS (Atlanta Biologicals; Flowery Branch, GA),
1.5×10−4 M monothiolglycerol (MTG) (Sigma-Aldrich; St. Louis, MO), 100 ng/mL
murine stem cell factor (SCF) (PeproTech; Rocky Hill, NJ) and 10 ng/mL human

40

interleukin-6 (hIL-6) (PeproTech; Rocky Hill, NJ). Cells were maintained at 0.5×106
cells/mL and 2×106 cells/mL and kept at 37°C and 5% CO2 in a humidified cabinet. 293T
cells were cultured in DMEM (Gibco; Carlsbad, CA) with 10% FBS.

Drug Treatment
10mg/mL Tamoxifen (Sigma-Aldrich; St. Louis, MO) was resuspended in 10%
ethanol and 90% sunflower seed oil (Sigma-Aldrich; St. Louis, MO ). 1mg was
administered to mice via oral gavage each day for five consecutive days.

HSPC Isolation
Bone marrow was harvested from femurs, tibias, pelvic bones and spines of 10- to
14-week-old mice by crushing. c-Kit+ cells were enriched magnetically using anti-c-Kit
microbeads (Miltenyi Biotec; San Diego, CA) and an AutoMACS (Miltenyi Biotec; San
Diego, CA). Cells were then stained with fluorescently conjugated antibodies for Sca-1
(E13-161.7, BD Biosciences; San Jose, CA) and c-Kit (2B8, eBioscience, Inc.; San
Diego, CA) and HSPC (Lineage-Sca-1+cKit+) were isolated via cell sorting using a
FACSAria III (BD Biosciences; San Jose, CA). DAPI (Sigma-Aldrich; St. Louis, MO ;)
was used to exclude dead cells.

Antibody Production
Three peptides (peptide 1 (Q26-R46): QARKRKYFKKHEKRMSKDEER,
peptide 2 (V96-D110): VLSNPDQKGKIRRID, peptide 3 (T177-K195):
TPESGQSDSSNQQGDADIK) were designed based on the murine NFIX protein
sequence (P70257.2) and injected into three cohorts of mice. Sera were then collected
from injected mice and screened in both enzyme-linked immunosorbent assay (ELISA)
using the respective peptide bound to the plate and a flow-based screening technique. The
flow-based assay used paramagnetic streptavidin (SA) beads (Promega; Madison, WI),
biotinylated rat anti-FLAG monoclonal antibody (mAb) (LSBio; Seattle, WA), goat antimouse IgG (H+L) rat adsorbed (SouthernBiotech; Birmingham, AL), cellular lysate from
293T cells transfected with either a FLAG-NFIX overexpression vector or a GFP
expression control vector, and a FACSCalibur cell analyzer with CellQuest Pro software
for analyses. This was performed by incubating the SA beads with the biotinylated antiFLAG mAb at 4C in one tube and the lysate with sera (diluted 1:100 in the lysate) in a
second tube at 4C overnight. The beads were washed three times to removed unbound
mAb. The lysate/sera mixture was then added to the beads and allowed to incubate at 4C
for a minimum of four hours or overnight. Following the incubation, beads were washed
and stained with the goat anti-mouse IgG secondary at a 1:1000 dilution for 30 minutes
on ice. Beads were then analyzed by flow cytometry. This assay identified peptide three
as the most promising and the mouse with the highest titer was selected for fusion.
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Briefly, the spleen was harvested and splenocytes fused to an equal number of
Sp2/mIL-6 (ATCC® CRL-2016™) cells [124]. The fusion was transferred to 96 well
plates and incubated in HAT (Sigma-Aldrich; St. Louis, MO) supplemented media
(ClonaCell-HY Medium E, Stemcell Technologies; Vancouver, BC) for 10 days. The
supernatants from wells containing clones were then screened by an ELISA for reactivity
to the peptide. Positive wells were then transferred to 24 well plates and supernatant was
used in the SA bead/lysate assay as described above. The cells from positive wells in this
assay were then single cell sorted into 96 well plates to confirm they were monoclonal.
Generation of Nfix-/- HPC5 Cells
Nfix-/- HPC5 cells were generated using clustered, regularly interspaced,
palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9). Briefly, short
guide RNAs (sgRNAs) were designed with at least three base pairs of mismatch to any
other site in the mouse genome to mitigate the risk of off-target editing. 500,000 HPC5
cells were transiently co-transfected with 0.5 µg pmaxGFP plasmid (Lonza; Basel,
Switzerland), 33 pmol spCas9 protein and 100 pmol chemically modified sgRNAs (5’ucagauaguucaaaccagca -3’) (Synthego; Redwood City, CA) via nucleofection (4DNucleofector X-unit, Lonza; Basel, Switzerland), using solution P3 and program CA-137
in a small (20 µL) cuvette according to the manufacturer’s recommended protocol. Five
days post nucleofection, cells were single-cell sorted by FACS to enrich for GFP+
(transfected) cells, clonally expanded, and verified for the desired modification via
targeted deep sequencing using gene specific primers with partial Illumina adapter
overhangs (mNfix.F – 5’ ccctggagcctgggtgaacaaggtc-3’ and mNfix.R – 5’
ccgacccttcagcgcttccccacta-3’, overhangs not shown). Next generation sequencing (NGS)
analysis of clones was performed using CRIS.py [125].

Chromatin Immunoprecipitation and Library Preparation
20 million Nfix+/+ and Nfix-/- HPC5 cells were fixed with 1% formaldehyde
(Sigma-Aldrich; St. Louis, MO ) for 10 minutes at room temperature with gentle stirring.
Fixing was quenched with 0.125 M glycine (Sigma-Aldrich; St. Louis, MO) and further
stirring for five minutes at room temperature. Cells were collected by centrifugation and
snap frozen for storage at -80°C. Cells were then resuspended in buffer L1 (50mM
HEPES pH 7.5, 140mM NaCl, 1mM EDTA pH 8.0, 10% glycerol, 0.5% NP40, 0.25%
Triton X-100) supplemented with one Protease Inhibitor tablet (Roche; Basel,
Switzerland). During lysis, samples were kept on ice for 10 minutes with gentle agitation
every two minutes. Samples were centrifuged at 1693 rcf for 10 minutes at 4°C in a
swing bucket rotor. Supernatant was removed and cells were resuspended in buffer L2
(200mM NaCl, 1mM EDTA pH 8.0, 0.5mM EGTA, 10mM Tris pH8.0) supplemented
with one Protease Inhibitor tablet (Roche; Basel Switzerland). Samples were rocked at
room temperature for 10 minutes. Nuclei were isolated by centrifugation at 1693 rcf for
10 minutes at 4°C. Supernatant was carefully removed and 1X RIPA buffer was added to
samples. Nuclei were sonicated using a cell disruptor (SFX250) (Branson Ultrasonics
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Corporation; Brookefield, CT). Lysate was clarified with centrifugation at 18879 rcf for
15 minutes at 4°C. The supernatant was carefully transferred to a 15mL conical vial.
Samples were incubated with protein A/G sepharose beads (Pierce; Waltham, MA)
overnight to preclear supernatant. 20ug of each antibody listed in anti-PU.1 (sc-390405,
Santa Cruz; Dallas, TX) and anti-NFIX (clone: 7B5.3) antibodies were also pre-bound to
protein A/G agarose beads (Pierce; Waltham, MA) for overnight incubation. Pre-cleared
chromatin was centrifuged at 1000 rcf for three minutes at 4°C. Pre-cleared chromatin
was added to respective antibody-bead complex in Eppendorf tubes while some precleared chromatin was reserved for input. Samples were rotated at 4°C for four hours.
After incubation, samples were centrifuged at 5418 rcf for five minutes at 4°C.
Supernatant was aspirated and beads were washed with various buffers: once with IP
Wash Buffer I (20mM Tris pH8.0, 50mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1%
SDS), twice with IP High Salt Wash Buffer (20mM Tris pH8.0, 500mM NaCl, 2mM
EDTA, 1% Triton X-100, 0.1% SDS), once with IP Wash Buffer II (10mM Tris pH8.0,
250mM LiCl, 1mM EDTA, 1% NP-40, 1% deoxycholic acid), and twice with TE buffer.
DNA:protein complexes from beads were eluted twice with freshly made elution buffer
(1% SDS, 100mM sodium bicarbonate). To reverse crosslinking, 5M NaCl (final
concentration 370mM), 10mg/mL RNase (final concentration 0.45mg/mL), and
20mg/mL proteinase-K (final concentration 0.26mg/mL) were added to eluates and input
samples. Incubate samples at 37°C for 30 minutes, 45°C for 30 minutes, and 65°C
overnight. DNA was eluted using the Qiagen MinElute (Hilden, Germany) kit following
manufacturer’s protocol except DNA was eluted in 28uL with provided EB buffer. DNA
was quantified using the Quant-iT PicoGreen assay (Life Technologies; Carlsbad, CA)
Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific; Waltham, MA) or SpectraMax
Quant AccuBlue Pico dsDNA assay kit (Molecular Devices; San Jose, CA). Libraries
were prepared with KAPA HyperPrep Library Preparation Kits (KK8504) (Roche; Basel,
Switzerland). Libraries were analyzed for insert size distribution on a 2100 BioAnalyzer
High Sensitivity kit (Agilent Technologies; Santa Clara, CA), 5300 Fragment Analyzer
System HS Large Fragment Kit (Agilent Technologies; Santa Clara, CA), 4200
TapeStation D1000 ScreenTape assay (Agilent Technologies; Santa Clara, CA) or
Caliper LabChip GX DNA High Sensitivity Reagent Kit (PerkinElmer; Waltham, MA).
Libraries were quantified using the Quant-iT PicoGreen ds DNA assay (Life
Technologies; Carlsbad, CA) or low pass sequencing with a MiSeq nano kit (Illumina;
San Diego, CA). Single read 50 cycle sequencing was performed on a NovaSeq 6000
(Illumina; San Diego, CA) or NextSeq 550 (Illumina; San Diego, CA).

Peak Calling
The sequencing reads were mapped to the mouse genome (mm9) using BWA
(version 0.7.16a). ChIP-seq peaks were called using MACS2. De novo motif discovery
on ChIP-seq peaks was performed using HOMER (v4.9.1) [126] with parameters “-size
200 -mask”.
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RNA Extraction, Sequencing and Transcript-Level Abundance Calculation
RNA was extracted from 0.6x106-0.8x106 cells using the Qiagen RNeasy Mini
kit (Hilden, German) according to the manufacturer, including the on-column DNase
digestion. RNA was quantified using the Quant-iT RiboGreen assay (Life Technologies;
Carlsbad, CA) and quality checked by 2100 Bioanalyzer RNA 6000 Nano assay (Agilent
Technologies; Santa Clara, CA), 4200 TapeStation High Sensitivity RNA ScreenTape
assay (Agilent Technologies; Santa Clara, CA), or LabChip RNA Pico Sensitivity assay
(PerkinElmer; Waltham, MA) prior to library generation. Libraries were prepared from
total RNA with the TruSeq Stranded mRNA Library Prep Kit according to the
manufacturer’s instructions (20020595, Illumina; San Diego, CA). Libraries were
analyzed for insert size distribution on a 2100 BioAnalyzer High Sensitivity kit (Agilent
Technologies; Santa Clara, CA), 4200 TapeStation D1000 ScreenTape assay or Caliper
LabChip GX DNA High Sensitivity Reagent Kit (PerkinElmer; Waltham, MA). Libraries
were quantified using the Quant-iT PicoGreen ds DNA assay (Life Technologies;
Carlsbad, CA) or low pass sequencing with a MiSeq nano kit (Illumina; San Diego, CA).
Paired end 100 cycle sequencing was performed on a NovaSeq 6000 (Illumina; San
Diego, CA). Transcript-level abundance was quantified using Kallisto [20] with pre-built
genome index for mm9 and differential analysis was done using Sleuth [21]. Source code
for Kallisto is available at: https://github.com/pachterlab/kallisto. Source code for Sleuth
is available at: https://github.com/pachterlab/sleuth.

Bioinformatics Pipeline Description
NFIX target genes were identified based on observed differential expression in
Nfix+/+ versus Nfix-/- HPC-5 cells and binding to either gene promoters (+- 10kb around
TSS, ensembl v67) or enhancers (based on CaptureC experiments from GSE119339).
NFIX peaks were then extracted and used to search for co-binding factors, including
SCL/TAL1, LYL1, LMO2, GATA2, RUNX1, MEIS1, PU.1, ERG, FLI-1 and GFI1B
(GSE22178). Co-binding analysis based on Chi-square test was performed at both in vivo
transcription factor binding sites (i.e., ChIP-seq peaks) and in-silico for known motifs).
Source code is available at: https://github.com/YichaoOU/TF_target_finder.
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CHAPTER 3.

NFIX IS DISPENSABLE DURING HSPC TRANSPLANT AND
STEADY STATE HEMATOPOIESIS

Introduction
Transplant-induced stress exerted on HSPC has been well documented, resulting
in reduced stem cell pools and decreased self-renewal ability [127-129]. Regulation of
their ability to overcome this stress and successfully replenish hematopoiesis is not well
understood. Cell-extrinsic and cell-intrinsic regulators of HSCT have been implicated in
HSPC self-renewal, mobilization and homing (see Figure 1-6 and Tables 1-1, 2)
(reviewed in [130]) [131-133]. Better understanding the mechanisms that allow HSPC
engraftment post-transplant will facilitate efforts to improve transplantation protocols and
clinical outcomes.
Recently, our lab completed a functional screen that identified 18 novel regulators
of murine HSCT, including Nfix [86]. NFI family members function as transcriptional
activators and repressors [116 134]. NFIX and NFIA, a related family member, have also
been implicated in regulating hematopoietic lineage fate decisions, with ectopic
expression of NFIA or Nfix promoting HSPC differentiation to erythropoiesis or
myelopoiesis and depletion promoting granulopoiesis or lymphopoiesis, respectively
[115 135]. Although Nﬁx-/- mice display no overt hematopoietic phenotypes during native
hematopoiesis, shRNA-mediated knockdown or genetic deletion of Nﬁx in HSPC results
in a profound loss of competitive in vivo repopulating potential and increased apoptosis
[117]. However, it is prudent to validate shRNAs specificity.
Thus, we sought to better characterize the function of Nfix during hematopoiesis
utilizing a mouse model where Nfix could be spatially and temporally deleted in vivo in
hematopoietic cells, avoiding the use of viral integration and shRNAs. Also, to our
knowledge, no work has been done characterizing the hematopoietic compartment of
NfixΔ/Δ mice.

Results and Discussion

Nfix-shRNA Do Not Specifically Target Nfix
The second exon of Nfi family members consists of the DNA binding domain
[101]. This exon has been targeted for deletion by insertion of loxP sites in the introns
flanking the entire second exon [110]. We crossed this Nfixflox/flox mouse with a Rosa26Cre-ERT2 mouse model. We show consistently that in Nfixflox/flox Rosa26-Cre-ERT2 mice
treated with Tamoxifen there is near 100% deletion in HSPC (Figure 3-1A, B).
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Figure 3-1. Genotyping isolated colonies grown in methylcellulose.
(A) Top, colonies were collected from methylcellulose that had previously been plated
with 300 HSPC from Tamoxifen-treated Nfixflox/flox Rosa26-Cre-ERT2, except in lane 1
and lane 3. In lane 1 and lane 3, these represent colonies from Nfix+/+ Rosa26-Cre-ERT2
mice treated with Tamoxifen. In lane 5 and lane 8, the floxed allele is still detected,
suggesting partial deletion. Lower, genotyping confirming the colonies have a Cre allele.
(B) Genotyping of colonies were collected from methylcellulose that had previously been
plated with 300 HSPC from Tamoxifen-treated Nfix+/flox Rosa26-Cre-ERT2. Expected
amplicon sizes: Nfix+/+ = 214bp, Nfixflox/flox= 400bp and NfixΔ/Δ= 309bp.
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HSPC were isolated from Tamoxifen-treated Nfixflox/flox Rosa26-Cre-ERT2 (denoted as
NfixΔ/Δ) and transduced these HSPC with the Nfix-shRNA used previously in Holmfeldt
et al. [117]. The Nfix-shRNA transduced NfixΔ/Δ HSPC were transplanted into lethally
irradiated recipient mice with mock transduced competitor cells (CD45.1+). Four weeks
post-transplant the PB was taken from recipient mice and analyzed for donor cell
chimerism. Previously, when HSPC were treated with Nfix-shRNAs, there was a
significant decrease in donor cell chimerism seen as early as four weeks post-transplant
[117]. We observed no significant difference in the frequency of donor cell chimerism
measured as %mCherry+ CD45.2+ between recipients of Nfix+/+ HSPC transduced with
Nfix-shRNA and NfixΔ/Δ HSPC transduced with Nfix-shRNA (Figure 3-2). These data
strongly imply the shRNA used to target Nfix is not specific. Transplantation with two
other Nfix-shRNAs were attempted, however, the transduction efficiencies (%mCherry+)
were not consistent across cohorts. More work may be necessary to identify an shRNA
that specifically targets Nfix. Of note, there is no difference in donor cell chimerism
between recipients transplanted with Nfix+/+ HSPC or NfixΔ/Δ HSPC. If Nfix was necessary
during HSCT, we would have expected a decrease in donor cell chimerism in PB of
recipient mice. The experiment in Figure 3-2 was terminated four weeks post-transplant.
Perhaps, in our genetic deletion model, we would need to allow for more time to observe
a phenotype. The pool of cells we are transplanting (i.e. HSPC) is a heterogeneous mix of
stem and progenitor cells. Acutely post-transplant, transplanted progenitor cells give rise
to the PB lineages [136]. Thus, perturbations in donor cell chimerism early posttransplant may implicate defects with progenitor cells. Perturbations observed later posttransplant may indicate functionally compromised HSC. In order to further assess the
necessity of Nfix, we performed competitive transplants with Nfix+/+ and NfixΔ/Δ HSPC.

Nfix Is Dispensable for Murine HSCT
To mirror the acute deletion of Nfix, similar to that when shRNAs were used, we
isolated HSPC from Nfix+/+ Rosa26-Cre-ERT2 and Nfixflox/flox Rosa26-Cre-ERT2 mice.
These cells were treated with 4-Hydroxytamoxifen (4-OHT), the active metabolite of
Tamoxifen, in vitro for 24 hours. After 24 hours, the HSPC were mixed 1:1 with
CD45.1+ HSPC and transplanted into lethally irradiated recipient mice. Every four weeks
post-transplant, PB was sampled from the recipient mice and donor chimerism as well as
frequency of PB lineages was examined. We observed only a modest increase in PB
chimerism 12 and 16 weeks post-transplant (Figure 3-3, top left). We also see a modest
increase in the lymphoid lineage of the PB in recipients (Figure 3-3, lower left and
right). There is no difference in the donor chimerism in the myeloid lineage
(Figure 3-3, top right). These results suggest that perhaps the HSC are more
proliferative and may exhaust if stressed further. To interrogate this hypothesis, we
performed secondary transplants. Whole BM (WBM) from primary transplant recipients
was collected and 1x106 WBM cells were transplanted in lethally irradiated secondary
recipients. At this time, 0.04x106 WBM cells were plated in methylcellulose in order to
interrogate the deletion efficiency of cells. As previously mentioned, every four weeks
post-transplant, PB was sampled from the recipient mice and donor chimerism as well as
frequency of PB lineages was examined. At no point during these secondary transplants
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Figure 3-2. %mCherry+ CD45.2+ frequency in PB of recipient mice transplanted
with NfixΔ/Δ HSPC transduced with Nfix-shRNA.
Four weeks post-transplant the %mCherry+ CD45.2+ frequency of donor chimerism in
recipients of NfixΔ/Δ HSPC transduced with Nfix-shRNA and Nfix+/+ HSPC transduced
with Nfix-shRNA is not significantly (NS) different. N=4-3 mice/cohort. One-way
ANOVA followed by Tukey post-hoc test. *P < 0.05, **P < 0.01.
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Figure 3-3. Frequency of PB chimerism and lineages in primary NfixΔ/Δ
transplants.
Top left, Frequency of PB chimerism in recipient mice. At 12 and 16 weeks posttransplant we observed a modest but significant increase in PB chimerism. Lower left,
frequency of donor-derived B-cells in PB of recipients. At 12 and 16 weeks posttransplant we observed a modest but significant increase in B-cell chimerism. Lower
right, frequency of donor-derived T-cells in PB of recipients. At 12 and 16 weeks posttransplant we observed a modest but significant increase in T-cell chimerism. Top right,
there was no significant difference in the frequency of donor-derived myeloid cells
comparing recipient mice transplanted with NfixΔ/Δ HSPC (◼) and Nfix+/+ HSPC (⚫).
N=4-5 independent transplants, 4-5 mice/cohort. A two-way ANOVA with Sidak’s
multiple comparisons test was performed to determine significance. *P = <0.05.
**P = <0.01

49

were there any significant differences revealed (Figure 3-4). These data suggest there are
no functional defects in NfixΔ/Δ HSC.
In sum, we find the Nfix-shRNA used initially does not specifically target Nfix.
The primary and secondary transplants presented support a model where Nfix may be
unnecessary during stress hematopoiesis. These data may be confounded by
compensation from other Nfi family members. We find both Nfic and Nfia are expressed
throughout the hematopoietic hierarchy. However, neither Nfic nor Nfia KO models
display hematopoietic defects. This suggests there may be compensation or redundancy
within the family and alludes to the importance of Nfi expression during hematopoiesis.

Deletion of Nfix Does Not Perturb Steady-State Hematopoiesis
To determine the importance of Nfix at steady-state hematopoiesis we utilized a
mouse model where we could spatially and temporally delete Nfix in hematopoietic cells,
including HSPC. We crossed Nfixflox/flox mice with HSC-Scl-Cre-ERT mice to generate
Nfixflox/flox HSC-Scl-Cre-ERT mice. Controls were Nfixflox/flox without HSC-Scl-Cre-ERT
knockin (KI) allele. Nfixflox/flox mice and Nfixflox/flox HSC-Scl-Cre-ERT (denoted NfixΔ/Δ
after treatment with Tamoxifen) mice were treated with Tamoxifen for five consecutive
days via oral gavage. This mouse model also exhibits efficient deletion of Nfix in HSPC.
Peripheral blood from these mice were collected for 47 weeks (Figure 3-5). At no point
were there any significant differences in PB lineages comparing Nfixflox/flox mice and
NfixΔ/Δ mice. These mice also retained the complete deletion of Nfix in HSPC after 47
weeks and had normal complete blood counts (CBC).
In conclusion, we have discovered that our Nfix-shRNA does not specifically
target Nfix. We also show that during primary transplants with NfixΔ/Δ HSPC there is a
slight but significant increase in donor cell chimerism as well as an increase in donorderived lymphoid cells at 12- and 16-weeks post-transplant. This phenotype later in the
transplant suggests that NfixΔ/Δ HSC may be cycling faster and eventually exhaust
resulting in defective performance during another round of stress hematopoiesis. To test
this hypothesis, we performed secondary transplants with WBM from primary transplant
recipients. In these transplants, we did not observe any significant differences in donorcell chimerism or PB lineages. It may be interesting to repeat the primary transplants but
include a different stress, such as, polyI:polyC (pIpC) or 5-fluorouracil (5-FU) treatment.
Repeated treatments may be necessary to stress the NfixΔ/Δ HSC. The modest increase in
B-cell and T-cell lineages may suggest NFIX regulates lineage-specific transcriptional
programs. Our data are in agreement with previous observations where it enforced Nfix
resulted in increased myelopoiesis at the expense of lymphopoiesis [137]. In another
cellular context, during skeletal muscle development NFIX acts as a switch to activate a
fetal transcriptional program while repressing embryonic gene expression [118]. ChIPseq and RNA-seq in the T- and B-cell lineages using NfixΔ/Δ samples may reveal NFIX
functions similarly during hematopoietic lineage determination.
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Figure 3-4. Frequency of PB chimerism and lineages in secondary NfixΔ/Δ
transplants.
The secondary transplants utilizing WBM from primary transplants reveals no significant
differences in donor-cell chimerism or donor-derived lineages. N=2-4 independent
transplants, 4-5 mice/cohort. A two-way ANOVA with Sidak’s multiple comparisons test
was performed to determine significance.
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Figure 3-5. Frequency of PB lineages comparing NfixΔ/Δ mice and Nfix+/+ mice.
N=2 independent cohorts, 6-7 mice/genotype. Student’s T-test was used to determine
significance. Errors bars represent standard error (SE).
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CHAPTER 4.

ENFORCED NFIX PROMOTES SURVIVAL OF IMMATURE
HEMATOPOIETIC CELLS EX VIVO3

Introduction
In the previous chapter, our data suggested that Nfix was not necessary for HSCT
or to maintain steady-state hematopoiesis. This finding could result from redundancy or
compensatory mechanisms from other Nfi family members, especially Nfia or Nfic,
suggesting the importance of the gene family for hematopoiesis. Previously, both NFIA
and Nfix were shown to promote HSPC differentiation [115 135], however, little is
known about how NFIX regulates HSPC at the molecular and cellular level. Here we
report that enforced Nfix can promote ex vivo growth, cytokine hypersensitivity, and
survival of primitive hematopoietic populations ex vivo. We further demonstrate that
these effects are in part mediated via up-regulation of the TPO receptor, c-Mpl, thus
revealing NFIX as a novel transcriptional regulator of c-Mpl and illuminating one
molecular pathway targeted by NFIX in HSPC.

Results and Discussion

Nfix Extends the Ex Vivo Growth of Immature Hematopoietic Cells
To further interrogate the role of Nfix in HSPC biology, we ectopically expressed
Nfix in Lineage−Sca-1+c-Kit+ (LSK; HSPC) cells cultured under serum-free conditions
(Figure A-1A). During culture, cells were assessed for growth rate, retention of vector+
(NFIX+) cells, and persistence of an LSK phenotype (Figure 4-1A). Nfix was overexpressed 20-fold in NFIX+ cells, while other NFI genes remained unperturbed (Figure
4-1B). Remarkably, ectopic Nfix expression prolonged hematopoietic cell cultures twofold, allowing cells to persist up to 40 days ex vivo (Figure 4-1C). However, the relative
growth of control and NFIX+ cultures did not significantly diverge until control cells
began to display culture exhaustion (p = 0.036) (Figure 4-1C). During this extended
time, a steady selection for NFIX+ cells was apparent (Figure 4-1D). These data suggest
that Nfix can promote the extended cell culture of hematopoietic progenitors. By seven
days of culture, the majority of cells in both control and NFIX+ cultures had lost the LSK
cell surface phenotype (Figure 4-1E), with immunophenotypic LSK cells being almost
completely lost from culture by day 14 (Figure A-1B, C).
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Figure 4-1. Nﬁx induces longevity in hematopoietic stem and progenitor cell ex
vivo culture.
(A) Experimental schematic. 48 hours post-transduction, LSK cells transduced with
MND-Control or MND-Nfix were re-plated in 96-well non-tissue culture treated plates in
serum-free expansion medium (SFEM) supplemented with mSCF, mTPO, mIGF-2, and
hFGF-a (STIF). Every 48-72 hours of culture, cells were counted, assessed for GFP+
cells, and passaged 1:4. Cells were also periodically assessed for LSK immunophenotype. (B) Relative expression of NFI-family genes in NFIX+ cells compared to
control cells, quantified by qRT-PCR (n = 3). Tbp was used as a housekeeping gene. (C)
Relative growth of control and NFIX+ cells during ex vivo culture (n = 4). Dotted line
indicates the divergence in relative growth between control and NFIX+ cells. (D) GFP
percentage of control and NFIX+ cells during ex vivo culture, assessed by flow cytometry
(n = 4). (E) Percentage of control and NFIX+ cells with an LSK immuno-phenotype at
day seven of ex vivo culture, depicted as a (top) representative dot plot and (lower) bar
plot (n = 6). All values represent mean ± standard deviation. NS denotes not significant.
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However, Nfix overexpression appeared to accelerate the loss of this phenotype,
evident by the appearance of a Sca-1−c-Kit− population in NFIX+ cells and reduced
overall levels of cell surface c-Kit, relative to control (Figure 4-1E, top and lower and
Figure A-1D). These data suggest that Nfix might promote LSK cell differentiation
during ex vivo culture. At day seven of culture, control and NFIX+ cells displayed a
similar blast-like morphology, with NFIX+ cells retaining this morphology through day
30 of culture (Figure A-2). However, LSK cells overexpressing Nfix displayed a loss of
in vivo competitive hematopoietic repopulating potential, a myeloid bias in peripheral
blood production and a loss of CFU potential compared to control cells by seven days of
culture, with a significant loss in CFU potential by 21 days in culture
(p = 0.023) (Figure A-3A through D and Figure A-4). A majority of expanded control
and NFIX+ cells were negative for all major lineage markers (except CD8) and expressed
c-Kit and CD71, which is a marker of proliferating progenitors
(Figure A-5A, B). High CD71 expression can also be indicative of erythroid progenitors,
and while NFIX+ cells show a significantly higher percentage of a CD71hi population
compared to controls (p = 0.017), this population represents only a small portion (1525%) of cells throughout the entirety of the culture (Figure A-5C). Together, these data
suggest that Nfix promotes differentiation of LSK cells towards a heterogeneous
immature progenitor population that ultimately lacks CFU potential, suggesting arrested
differentiation potential.

Enforced Expression of Nfix in HSPC Results in Hypersensitivity to Growth
Cytokines and Protection From Apoptosis
This unimpeded growth led us to question if the cells were resistant to apoptosis
or accelerating through the cell cycle. Towards this, NFIX+ HSPC were cultured under
normal or reduced cytokine conditions and monitored for growth rate, NFIX+ cell
selection, cell cycle, and apoptosis (Figure 4-2A). Control cells cultured in reduced
cytokines displayed a significantly lower growth rate by day 13 (p = 0.048) and an
attenuated culture lifespan relative to cells maintained at normal cytokine levels
(Figure 4-2B). Remarkably, reduced cytokine levels had no effect on the extended
culture of NFIX+ cells (Figure 4-2B). NFIX+ cells cultured under reduced cytokines
were selected for at a significantly accelerated rate compared to NFIX+ cells cultured
under normal cytokine levels (p = 0.041) (Figure 4-2C). There were no significant
differences in cell cycle status between control and NFIX+ cells regardless of cytokine
levels (Figure 4-2D), suggesting that the reduced growth rate of cytokine-deprived
control cells was not due to a reduction in cycling. However, control cells displayed a
significant increase in apoptosis (p = 0.032) when cultured in reduced cytokines
(Figure 4-2E). In contrast, the apoptotic status of NFIX+ cells was unaffected by reduced
cytokines (Figure 4-2E), even in immunophenotypic HSPC (Figure A-6). These data
reveal that Nfix promotes primitive hematopoietic cell survival ex vivo.
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Figure 4-2. Hematopoietic stem and progenitor cells overexpressing Nﬁx can
withstand cytokine deprivation and display reduced apoptosis during ex vivo
culture.
(A) Experimental schematic. 48 hours post-transduction, LSK cells transduced with
MND-Control or MND-Nfix were re-plated in 96-well non-tissue culture treated plates in
serum-free expansion medium (SFEM) supplemented with either normal (100%) or
reduced (25%) levels of STIF cytokines. Every 48-72 hours of culture, cells were
counted, assessed for GFP+ cells, and passaged 1:4. Cells were also assessed by flow
cytometry for apoptosis via Annexin V and cell cycle via DAPI at day seven of culture.
(B) Relative growth of control and NFIX+ cells during ex vivo culture (n = 4). Dotted
line indicates the divergence in relative growth between control 100% and control 25%
cells. (C) GFP percentage of control and NFIX+ cells during ex vivo culture, assessed by
flow cytometry (n = 4). Dotted line indicates significant selection of NFIX+ cells under
25% cytokines. (D) Cell cycle analysis of GFP+ control or NFIX+ cells at day seven of
ex vivo culture (n = 3). (E) Percentage of GFP+ apoptotic cells within control or NFIX+
cell cultures at day seven of ex vivo culture (n = 6). All values represent mean ± standard
deviation. NS denotes not significant.
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c-Mpl Expression Is Increased in Nfix Overexpressing Cells
We previously observed by global gene expression analyses [117]that Nfix
knockdown in HSPC reduced expression of multiple genes implicated in HSPC survival
and maintenance including c-Mpl, a known regulator of HSC maintenance in the bone
marrow niche that has been shown to affect apoptosis via multiple downstream signaling
cascades [138-141]. c-MPL is the receptor for TPO, which is added as a supplement to
our ex vivo serum-free cultures of HSPC. To further explore possible regulation of c-Mpl
levels by NFIX, we assessed the expression of c-Mpl in NFIX+ cells after seven days of
ex vivo culture by qRT-PCR and flow cytometry (Figure 4-3A, B). We found that c-Mpl
transcripts increased two-fold in NFIX+ cells (p = 0.028) (Figure 4-3A). We also
observed a two-fold increase in c-MPL cell surface antigen on NFIX+ cells relative to
control via flow cytometry (p = 0.042) (Figure 4-3B top and lower). Also, from the
number of additional HSPC genes previously observed to be perturbed by loss of Nfix
[117], Erg was significantly upregulated (p = 0.022) (Figure A-7). TPO/c-MPL signaling
is classically involved in megakaryopoiesis and platelet production [142-144]. Thus, as
expected, NFIX+ cells also displayed a substantial increase in the cell-surface antigen
CD41 (Figure 4-3C left and right), a known marker of megakaryocytes [145]. Since our
data suggested that Nfix was driving HSPC towards an immature progenitor population
(Figure A-2 through 5), we further interrogated our cultures for
CFU-Megakaryocytes (CFU-Megs). NFIX+ cells appeared to generate more CFU-Megs
than control cells after seven days of culture (p = 0.052), but the absolute frequency of
CFU-Megs in NFIX+ cultures was minute (0.016), revealing that megakaryocytic
progenitors with colony forming potential are rare in NFIX+ cultures
(Figure A-8B). This is consistent with the observed low percentage of
immunophenotypic megakaryocyte progenitors
(c-Kit+Sca-1−CD127−CD9+CD32/CD16loCD41+) (Figure A-8C) [146]. Indeed, by day
30 almost no CFU-Megs were present in NFIX+ cultures (Figure A-8A).
TPO/c-MPL can activate JAK/STAT, PI3K/AKT, and MAPK/ERK downstream
signaling pathways [147]. To determine if NFIX-mediated up-regulation of c-Mpl also
increased TPO/c-MPL signaling, we examined the phosphorylation status of STAT5,
AKT, and ERK1/2 via flow cytometry. NFIX+ cells displayed significant enhancement
of STAT5 phosphorylation compared to control cells (p = 0.018), while AKT trended
towards enhanced phosphorylation after prolonged TPO treatment (Figure 4-3D, left,
middle, right and Figure A-9A). Also, NFIX+ cells showed no difference in
phosphorylation of ERK1/2 compared to control cells (Figure 4-3D, right and Figure
A-9A). This suggests that the anti-apoptotic effects displayed by NFIX+ HSPC may be
mediated through the STAT5 signaling pathway. Indeed, expression of Bcl-XL, an antiapoptotic factor induced by STAT5 [148], was also significantly upregulated in NFIX+
cells by two weeks of culture compared to controls (p = 0.0038) (Figure A-9B). In sum,
these data reveal that up-regulation of Nfix induces both
c-Mpl expression and signaling downstream of c-MPL in primitive hematopoietic cells.
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Figure 4-3. NFIX upregulates c-Mpl expression and downstream signaling in
HSPC during ex vivo culture.
(A) Expression of c-Mpl in LSK cells transduced with MND-Nfix relative to controls at
day seven of culture, quantified by qRT-PCR (n = 3). Tbp was used as a housekeeping
gene. (B) Percentage of c-MPL+ cells at four days of ex vivo culture for control and
NFIX+ HSPCs, depicted as (top) representative dot plots and (lower) bar plots (n = 3).
(C) Relative level of CD41 cell surface expression in NFIX+ cells compared to controls
after four days of ex vivo culture, measured by flow cytometry as gMFI, depicted as (left)
representative fluorescence histogram and (right) bar plot (n = 3). (D) Relative levels of
STAT5, AKT, and ERK1/2 phosphorylation in NFIX+ cells compared to controls after
four days of ex vivo culture, measured by flow cytometry as geometric mean fluorescence
intensity (gMFI). Depicted as (top) representative fluorescence histograms and (lower)
bar plots (n = 3). (E) (top) Quantitative ChIP analysis of c-Mpl proximal promoter in
HPC5 cells. Data are presented as a percentage of total input chromatin (n = 3). (lower)
Left, Schematic representation of the c-Mpl promoter with half and full NFI consensus
sites cloned into luciferase reporter backbone pGL4.14. Right, Results showing luciferase
activity normalized to Renilla luminescence and relative to MND-control samples
(n = 3-5). Values represent mean ± SE. NS denotes not significant.
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NFIX Regulates the Expression of c-Mpl
Examination of the c-Mpl locus revealed palindromic NFI binding sites within the
c-Mpl promoter (Figure 4-3E, lower). Promoter analysis by TRANSFAC revealed full
NFI consensus sites 101 and 127 nucleotides upstream of the c-Mpl transcription start site
(TTS, +1) (Figure 4-3E, lower). NFI members are known to bind both full and half NFI
consensus sites [149]. Two half sites were identified 18 and 189 nucleotides upstream of
the c-Mpl TSS (Figure 4-3E, lower). To assess NFIX transcriptional activity against
these putative NFI binding sites in the c-Mpl proximal promoter, a c-Mpl 243 bp genomic
fragment 5′ of the c-Mpl promoter containing the four identified putative NFI binding
sites was sub-cloned into the pGL4.14 promoterless luciferase vector. Transient
transfection of this vector into K562 cells yielded nearly three-fold higher levels of
promoter activity when co-transfected with MND-NFIX relative to co-transfection with
MND-Control (Figure 4-3E, lower). This enriched activity was diminished when the
half NFI site (−189) furthest from the TSS was removed and was significantly reduced by
the additional removal of the two full NFI sites (−127 and −101) (p = 0.0056)
(Figure 4-3E, lower). Further, chromatin immunoprecipitation (ChIP) was used to show
direct NFIX binding to the c-Mpl proximal promoter in the HPC5 bone marrow derived
cell line. Primers were designed and validated to amplify the promoter region containing
two full NFI consensus sites. In Figure 4-3E (top), a near 9-fold enrichment is observed
in samples where a FLAG-tagged NFIX is present compared to controls. These data
suggest that NFIX may directly activate c-Mpl promoter activity in a hematopoietic cell
line.

Nfix-Induced Protection From Apoptosis Can Be Abrogated by Blocking
c-MPL/TPO Signaling
To determine if the anti-apoptotic effects of ectopic Nfix in primitive
hematopoietic cells depends on enhanced TPO/c-MPL signaling, we cultured NFIX+
HSPC in reduced cytokines while also either removing TPO or blocking ligand binding
to c-MPL via a neutralizing antibody (AMM2) [138] for 72 hours. Although removal of
TPO and neutralization of c-MPL led to reduced cell expansion in both control and
NFIX+ cultures, NFIX+ cultures were significantly more sensitive to the loss of c-MPL
stimulation after TPO removal or the addition of AMM2 (p = 0.0021 and 0.033,
respectively) (Figure 4-4A, left and right). The selection for NFIX+ cells under reduced
cytokines was also lost when TPO/c-MPL signaling was blocked by TPO removal or the
addition of AMM2 (p = 0.0054 and 0.0019, respectively) (Figure 4-4B, left and right),
suggesting an enhanced reliance on TPO/c-MPL signaling for expansion of NFIX+ cells.
NFIX+ cells display an accelerated loss of the LSK immuno-phenotype (Figure 4-1E),
possibly due to enhanced differentiation towards a downstream progenitor
(Figure A-3 through 5). This loss of immuno-phenotype was mostly due to downregulation of c-Kit cell surface expression (Figure 4-1E, top). When NFIX+ cells were
culture in the absence of TPO or the presence of AMM2, c-Kit was no longer rapidly
down-regulated relative to control (Figure 4-4C). Finally, while apoptosis was relatively
unaffected by a loss of c-MPL signaling in control cells, NFIX+ cells displayed
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Figure 4-4. The antiapoptotic effect of Nﬁx in hematopoietic stem and progenitor
cell depends on c-MPL signaling.
(A) Relative number of cells in control and NFIX+ cultures (left) with or without TPO
and (right) with or without AMM2 72 hours after replating (TPO, n = 3; AMM2, n = 6).
Bar indicates significant difference in the extent of cell loss after 72 hours of culture
between control and NFIX+ cells. (B) Percentage of GFP+ cells in control and NFIX+
cultures (left) with or without TPO and (right) with or without AMM2 72 hours after
replating (TPO, n = 3; AMM2, n = 6). (C) Representative fluorescence histograms of
GFP+ control and NFIX+ cultures to illustrate shift in c-KIT intensity 72 hours after
removal of mTPO or addition of AMM2 (TPO, n = 3; AMM2, n = 6). (D) Relative levels
of apoptosis in GFP+ compartment of control and NFIX+ cultures (left) with or without
TPO and (right) with or without AMM2 72 hours after replating (TPO, n = 3; AMM2,
n = 6). All values represent mean ± standard deviation. NS denotes not significant.
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a significant increase in apoptosis after TPO removal (p =0.045) or addition of AMM2
(p = 0.0098) (Figure 4-4D, left and right). These data reveal that NFIX-mediated
up-regulation of c-MPL, and subsequent downstream signaling, functionally contributes
to Nfix-induced protection from apoptosis and accelerated differentiation in primitive
hematopoietic cells ex vivo.
In this study we have utilized ex vivo culture of HSPC to interrogate the molecular
regulation of HSPC by Nfix. HSPC overexpressing Nfix persist in culture significantly
longer than control cells, even when severely deprived of cytokines. We show that this
persistence is due to enhanced survival that is mediated, in part, by up-regulation of the
TPO receptor, c-Mpl. Nfix appears to promote differentiation of cultured HSPC towards a
heterogeneous mixture of immature progenitors that lack transplantation and CFU
potential (Figure A-2 through 5 and 8). We further demonstrate that NFIX may function
as a transcriptional regulator of c-Mpl. Indeed, NFIX was capable of activating a
promoter containing multiple NFI consensus binding sites located upstream of the c-Mpl
promoter. We also show NFIX-FLAG directly associated with the proximal promoter.
NFIX may also regulate downstream effectors of the TPO/c-MPL signaling pathway, as
Stat5a is significantly upregulated in NFIX+ cells compared to controls
(p = 0.0012) (Figure A-9C). We proposed the increased Bcl-xL may be driving
protection from apoptosis in NFIX+ cells. To test this hypothesis, we could collect HSPC
from Bcl-xLflox/flox Rosa26-Cre-ERT2 mice, transduce these cells with MND-Nfix and grow
these vector+ cells under reduced cytokines. A less specific method could be the use of a
BH3-mimetic drug or Roscovitine in NFIX+ cells. Roscovitine was initially used to
target STAT5, however, it has been shown to also affect cyclin dependent kinases
(CDK).
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CHAPTER 5.

CHARACTERIZATION OF GENOME-WIDE NFIX BINDING IN
HEMATOPOIETIC CELLS

Introduction
Nfix is well-characterized as a vital regulator of transcription in immature cells,
however, little is known about other direct transcriptional targets of NFIX in
hematopoietic progenitors. Furthermore, it is also currently unknown if NFIX
collaborates with other well-characterized transcriptional regulators of hematopoiesis. In
the previous chapter, we revealed data identifying a putative direct gene target of NFIX,
c-Mpl. Here, we sought to more broadly identify the direct transcriptional targets and
transcriptional partners of NFIX in HSPC.
Towards this goal, we created and validated an anti-NFIX mAb (clone: 7B5.3)
and an Nfix-/- hematopoietic cell line. We exploited these tools to perform anti-NFIX
ChIP-seq and RNA-seq in a hematopoietic context. These data allowed for comparison
with public ChIP-seq datasets, which implicated putative NFIX transcriptional partners.
Our results support a model in which NFIX and PU.1 collaborate to regulate genes
implicated in hematopoietic cell proliferation, apoptosis and differentiation.

Results and Discussion
To identify direct transcriptional targets of NFIX, we engineered an NFIXspecific mAb (clone: 7B5.3). Towards this, we identified a sequence downstream of the
DNA-binding domain that is conserved amongst NFIX splice variants (Figure B-1A). As
the NFI family members share homology in their N-terminal region [100], we assessed
the cross-reactivity of our anti-NFIX mAb with another NFI family member, NFIA.
Indeed, the anti-NFIX mAb exclusively immune-precipitated FLAG-NFIX in 293T cells
overexpressing FLAG-NFIX but not in samples overexpressing FLAG-NFIA (Figure
B-1B). In sum, we have engineered a mAb that specifically recognizes and immuneprecipitates FLAG-NFIX.

NFIX Binds Accessible and Inaccessible Regions of Chromatin
Due to the paucity of primary HSPC, we utilized HPC5 cells, an immortalized
hematopoietic progenitor cell line, as an experimental surrogate [150]. HPC5 cells derive
from adult murine bone marrow progenitors and express NFIX. To rigorously control for
antibody specificity, we exploited CRISPR-Cas9 technology to perform targeted editing
of Nfix. sgRNAs combined with Cas9 was employed to target a region in the third exon
of Nfix (Figure B-2A). Successfully transfected clones were isolated, expanded and
sequenced to assess insertion and deletions (InDels) in the targeted region of Nfix. A
clone was identified with InDels in both Nfix alleles: a 10 bp InDel and a seven bp InDel,
each of which resulted in frameshifts and multiple pre-termination codons
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(Figure B-2A). Nfix expression was decreased by 70% in this targeted clone relative to
parental HPC5 cells (Figure B-2B). In contrast, Nfic and Nfia were upregulated by 40%
and 48%, respectively, in Nfix-/- HPC5 cells compared to parental HPC5 cells (Figure
B-2B). Consistent with our previous findings [117], c-Mpl expression was decreased by
about 25% in Nfix-/- HPC5 cells relative to parental HPC5 cells (Figure B-2B).
Exploiting our NFIX-specific mAB, we performed ChIP-seq using chromatin
from Nfix+/+ and Nfix-/- HPC5 cells. We recorded 6,831 total peaks from Nfix+/+ samples.
NFIX peaks observed in Nfix+/+ cells were significantly enriched for the NFI-binding
motif sequence (p = 1x10-1844) (Figure 5-1A). Conversely, Nfix-/- samples show no
enrichment for the NFI-binding motif (Figure 5-1B) and 98% of peaks appearing in
Nfix+/+ samples were absent from Nfix-/- samples. The only enriched motifs identified in
Nfix-/- cells belonged to MAFB (p = 1x10-14) and SRF (p = 1x10-13)
(Figure 5-1B). NFIX peaks were also enriched for ETS-binding motifs and the
MYOGENIN-binding (MYOG) motif (p = 1x10-51 and 1x10-17, respectively)
(Figure 5-1A). An NFI family member was previously shown to complex with and
enhance the transcriptional activity of MYOG [151]. Further, the NFI-binding motif is
present in the MyoG promoter. However, we do not find NFIX binding to promoter or
enhancer regions of MyoG in HPC5 cells. Together, these results indicate the high
specificity of our novel antibody. We also found NFIX binding enriched in promoter
regions and 5’-untranslated regions (UTR) of the HPC5 cells genome (Figure 5-1C).
NFI proteins have been shown to bind genomic regions associated with
methylated histone marks, such as histone 3 lysine 4 mono-methylation (H3K4me1) and
histone 3 lysine 4 tri-methylation (H3K4me3) [152]. These marks tend to display
enrichment in active enhancer and transcription start genomic regions, respectively [26].
NFIX binding has also been seen to correlate with the enhancer-associated histone mark,
histone 3 lysine 27 acetylation (H3K27ac) [121]. Thus, we performed ChIP-seq against
H3K4me1, H3K4me3 and H3K27ac using Nfix+/+ HPC5 cell-derived chromatin. We
observed an enrichment of H3K4me1 histone marks centered around NFIX peaks
(Figure 5-2A), confirming NFIX binding in enhancer regions. We found additional
histone marks, such as H3K4me3 and H3K27ac, also enriched around NFIX binding
(Figure 5-2B, C, respectively). Thus, NFIX binds active promoters and enhancers.
Promoters and/or CCCTC-binding factor (CTCF) often demarcate chromatin
domain boundaries [153]. NFIX is known to also associate with chromatin boundaries
[152]. We thus assessed the co-localization of CTCF and NFIX. We find NFIX and
CTCF peaks overlap in HPC5 cells (Figure 5-3A), indicating that NFIX might also have
a function at chromatin boundaries. We performed ATAC-seq using our Nfix+/+ and Nfix-/HPC5 cells. These data suggest 55% of NFIX peaks bind to accessible regions of
chromatin in HPC5 cells (Figure 5-3B). Furthermore, the NFI motif is only present in
20% of these accessible regions (Figure 5-3B, light orange, p = 1x10-609). Conversely,
NFIX-occupied inaccessible chromatin were highly enriched for the NFI motif
(Figure 5-3B, light blue, p = 1x10-2877). Recently, NFIB and NFIX were shown to
regulate chromatin accessibility at super-enhancers to maintain stem cell identity [154].
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Figure 5-1. NFIX is enriched in promoter regions of the HPC5 cell genome.
(A) HOMER de novo motif scanning reveals the NFI binding motif as the most significant motif detected in Nfix+/+ samples.
P = 1x10-1844; n=2. (B) For Nfix-/- samples, HOMER de novo motif scanning detected only the MAFB (P = 1x10-14) and SRF
(P = 1x10-13) binding motifs (n=2). (C) The log2 fold enrichment of NFIX peaks. NFIX is enriched in promoter regions and 5’UTR
regions (n=2). (D) Comparison of Nfix+/+ and Nfix-/- ChIP-seq tracks.
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Figure 5-2. NFIX significantly associates with active promoter and enhancers
histone marks.
(A) Enrichment of H3K4me1, H3K4me3 and H3k27ac signal centered around NFIX.
Left panel is signal plot showing H3K4me1 signal centered around NFIX. (B) Top, NFIX
binding with H3K4me1. Middle, NFIX and H3K4me3 binding near the Irs2 promoter.
Bottom, NFIX overlapping H3K27ac and H3K4me1 suggesting the presence of an active
enhancer. Promoter captureC from publicly available data is included to show NFIX
interacting with promoters from distant enhancers.
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Figure 5-3. CTCF and NFIX co-localize in HPC5 cells.
(A) CTCF read density centered around NFIX. (B) Top, 45% of NFIX peaks are located
in inaccessible regions of chromatin (blue) while the remaining are located in regions
with an ATAC-seq signal (orange). Lower, within accessible regions of chromatin where
NFIX peaks are found the NFI motif only makes up 20% of these targets however, still
highly enriched (p = 1x10-609). Inaccessible regions where NFIX is binding the NFI motif
accounts for 67% of these target regions and is highly enriched (left, light blue,
(p = 1x10-2877). (C) More than half of the identified super-enhancers also contain at least
one NFIX peak in HPC5 cells.
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Super-enhancers can be identified by binding of H3K27ac marks and large open regions
of chromatin. We were curious if NFIX binds to super-enhancers in our cellular context.
We found that NFIX overlaps with 52% of identified super-enhancers in HPC5 cells
(Figure 5-3C).

NFIX Functions as a Transcriptional Activator in Hematopoietic Cells
We next sought to identify direct transcriptional targets of NFIX in hematopoietic
cells. To better understand the transcriptional landscape regulated by NFIX, we
performed RNA-sequencing on Nfix+/+ and Nfix-/- HPC5 cells. We observed 531
differentially expressed genes (Figure 5-4A) (logFC=|1.0|, FDR<0.05). 80% of these
genes were down-regulated (Figure 5-4B). These data, combined with our data showing
NFIX binding is enriched for histone marks associated with active transcription, suggest
that NFIX acts as a transcriptional activator in hematopoietic cells. Globally, gene set
enrichment analysis (GSEA) also revealed that perturbed genes were enriched for gene
sets associated with p53 signaling, gene targets of HOXA9 and MEIS1, tumor necrosis
factor-alpha (TNF-α) signaling activation via nuclear factor κB, toll-like receptor
signaling and genes down-regulated in hematopoietic stem cells. Gene ontology (GO)
analysis using PANTHER revealed that the downregulated differentially expressed genes
were mostly involved in regulation of cell adhesion, proliferation and regulation of
immune system process (Figure 5-4C and Table B-1). Conversely, genes upregulated in
Nfix-/- HPC5 cells were not significantly associated with any GO terms.
To determine the direct gene targets of NFIX in HPC5 cells, we combined
promoter capture-C data (E-MTAB-3954), to identify enhancer regions, and known
transcription start site locations, to identify promoters, with our ChIP-seq dataset
(Figure 5-5A). This generated a list of putative NFIX target genes. We then filtered this
list with differentially expressed genes from our RNA-seq dataset (logFC=|1.0|,
FDR<0.05). This produced a list of 301 differentially expressed genes with NFIX binding
in enhancer or promoter regions. GO terms for these putative direct targets were related
to negative regulation of apoptosis in hematopoietic cells, positive regulation of
hematopoietic cell differentiation and proliferation, positive regulation of adaptive
immune response and cell-substrate adhesion (Table 5-1). Interrogating only the
downregulated NFIX-target genes showed GO terms associated with regulation of
localization, cell differentiation and regulation of cell adhesion. As expected, the NFI
binding motif was the most enriched known motif in NFIX peaks present in these
putative direct targets (p = 1x10-69) followed by NFIX and the NFI-half-site (Figure
5-5B). NFI family members are capable of binding NFI-half-sites [90]. Consensus
binding motifs for the known hematopoietic transcriptional regulators, RUNX and PU.1,
were also significantly enriched (p = 1x10-4 and 1x10-2, respectively) (Figure 5-5B). The
PU.1 motif is specifically enriched in NFIX peaks putatively targeting downregulated
genes (p = 1x10-52). RUNX1 is required for HSC emergence during development, is
expressed throughout the hematopoietic hierarchy and vital for HSC homeostasis [155].
PU.1 is also required for fetal hematopoietic development and necessary for
hematopoietic progenitor cell commitment and directs lymphpoiesis/granulopoiesis.
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Figure 5-4. NFIX functions as a transcriptional activator in HPC5 cells.
(A) Volcano plot showing 80% of differentially expressed genes (red dots) in Nfix-/- versus Nfix+/+ HPC5 cells are downregulated
(n=3). (B) GSEA plots reveal terms associated with the p53 signaling pathway, Hoxa9 and Meis1 targets, TNFα signaling and genes
associated with hematopoietic stem cells. Below each GSEA plot is a representative heatmap showing expression of genes that
significantly contribute to the leading edge of the analysis.

72

Figure 5-5. NFIX peaks regulating putative NFIX-target genes are enriched for NFI and PU.1 binding motifs.
(A) Target genes were identified based on observed differential expression in Nfix-/- versus Nfix+/+ HPC5 cells and binding to either
promoters or enhancers regions. NFIX peaks were then extracted and used to search for co-binding factors. (B) Homer de novo motif
scanning reveals the NFI consensus motif as significantly enriched in enhancer and promoter regions of direct gene targets
(p = 1x10-69). (C) Known PU.1 target genes are differentially regulated in Nfix-/- HPC5 cells. (D) Signal plots show ChIP peak
enrichment of key hematopoietic factors including, STAT3, PU.1, ETO2, RAD21, pSTAT1 and RUNX1 centered around NFIX ChIP
peaks.
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Table 5-1.
GO terms, determined by PANTHER analysis of genes directly
regulated by NFIX, suggests roles in regulating hematopoiesis.
Term
Regulation of response to external
stimulus

FDR
Genes
-4
1.32x10 Casp12, Tbxa2r, Lgmn, Nenf, Sema69,
Nupr1, Ly86, Dbn1, Dscam, Cd74,
Cd28, Nos2, Cdh5, Xrcc5, Tgm2,
Ephb2, Ccl5, Fgr, Socs3, Pvrl2,
Gpr183, Clcf1, Serpinf1, Phldb2

Myeloid cell differentiation

7.55x10-3 Cdkn1c, Hlf, Tspan2, Meis1, Tgfbr3,
Dab2, Tnfsf9, Sox6, Fam20c, Gpr183

Cell-cell adhesion via plasmamembrane adhesion molecules

1.93x10-3 Mpz, Celsr2, Alcam, Dscam, Celsr1,
Plxnb2, Cdh5, Epcam, Mag, Pvrl2

Regulation of lymphocyte apoptotic
process

4.23x10-2 Lgals3, Irs2, Cd74, Pdcd1, Ccl5

Positive regulation of angiogenesis

3.86x10-2 Prkcb, Tbxa2r, Pde3b, Lgals3,
Hmga2, Epha1, Cdh5, Emp2, Ccl5,
Serpinf1

Positive regulation of lymphocyte
proliferation

2.86x10-2 Tnfsf9, Cd74, Cd28, Ccl5, Gpr183,
Clcf1, Irs2

Notes: Genes listed are differentially expressed NFIX target genes that belong to the term
listed. FDR, false discovery rate.
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Indeed, multiple putative direct targets of NFIX are genes previously shown to be
transcriptionally regulated by PU.1 or their expression depends on PU.1 (Figure 5-5C)
[156-165].
To further assess if NFIX collaborates with key hematopoietic transcription
factors in gene regulation, we examined publicly available ChIP-seq data (GSE22178
andE-MTAB-3594) of the genomic binding of multiple hematopoietic transcription
factors (i.e. SCL/TAL1, LYL1, LMO2, GATA2, RUNX1, MEIS1, PU.1, ERG, FLI-1,
GFI1B, CEBPB, CFOS, CMYC, E2F4, EGR1, ELF1, ETO2, JUN, LDB1, MAX, MYB,
NF32, TP53, RAD21, pSTAT1, STAT3) in HPC7 cells [166]. HPC7 cells are a
hematopoietic progenitor cell line that was immortalized similarly to HPC5 cells [167].
Here, we compared the co-localization between the hematopoietic transcription
factor peaks in HPC7 cells with NFIX peaks found in promoters and enhancers in our
dataset. We observed significant co-localization with STAT3 (p = 3.429x10-4), RAD21
(p = 7.675x10-5), pSTAT1 (p = 9.840x10-6), ETO2 (p = 0.002), FLI1 (p = 0.004),
GATA2 (p = 0.008), LYL1 (p = 0.017), LDB1 (p = 0.041), RUNX1 (p = 9.640x10-6) and
PU.1 (p = 0.003) (Table 5-2) (Figure 5-5D). Indeed, 33% of PU.1 peaks in HPC7 cells
overlapped with NFIX peaks in HPC5 cells (Table 5-2). This analysis suggests that PU.1
and NFIX may collaborate to co-regulate a subset of target genes. In sum, NFIX may
cooperate other key hematopoietic transcription factors, including RUNX1 and/or PU.1,
to regulate target genes in HPC5 cells.

NFIX and PU.1 Co-Localize to Regulate Genes in Hematopoietic Cells
To validate these results, we performed ChIP-seq using a PU.1 antibody in Nfix+/+
and Nfix-/- HPC5 cells. Indeed, we found significant co-occupancy of PU.1 peaks and
NFIX peaks in Nfix+/+ and Nfix-/- HPC5 cells at promoter and enhancer regions
(p = 0.016 and 0.008, respectively) (Figure 5-6A). We generated a list of >40 target
genes based on NFIX and PU.1 co-localization (Figure 5-6C). GO terms associated with
genes targeted by both NFIX and PU.1 include many linked to cell adhesion, cell death
and differentiation (Figure 5-6B). Indeed, NFIX and PU.1 gene targets included Pdcd1,
Socs3 and Meis1 (Figure 5-6D). Additionally, we observed the PU.1 signal is
significantly less in the Nfix-/- HPC5 cells (p = <0.0001) (Figure 5-6D).These data
suggest that NFIX and PU.1 work together as transcriptional co-regulators to target genes
in hematopoietic cells.
In sum, we sought to identify the genome-wide binding, direct transcriptional
targets and transcriptional binding partners of NFIX. We have now shown that NFIX
preferentially binds at promoter and 5’UTR regions and associates with histone marks,
H3K4me1, H3K4me3 and H3K27ac. Our work reveals that NFIX mainly function as a
transcriptional activator in primitive hematopoietic cells. >300 putative direct targets of
NFIX (i.e. differentially expressed genes with NFIX occupying promoter or enhancer
regions of these genes) were identified using a novel mAb. NFIX and multiple key
hematopoietic transcription factors, including STAT3, RAD21, pSTAT1, ETO2, FLI1,
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Table 5-2.

Co-localization of key hematopoietic transcription factors with NFIX.

Transcription
factor
pSTAT1
RUNX1
RAD21
STAT3
ETO2
PU.1
FLI1
GATA2
LYL1
LDB1
LMO2
SCL
CEBPB
CMYC
EGR1
ELF1
TP53
JUN
MEIS1
MYB
E2F4
GFI1B
MAX
NF32
CFOS

Overlap of TF ChIP-seq peaks with
NFIX peaks (P-value)
9.840x10-6
9.640x10-6
7.675x10-5
3.429x10-4
0.002
0.003
0.004
0.008
0.017
0.041
0.064
0.078
0.079
0.188
0.231
0.359
0.414
0.481
0.498
0.498
0.592
0.657
0.787
0.800
0.959

% overlap of TF ChIP-seq
peaks with NFIX peaks
28.5
14.4
30.9
44.7
37.5
33.0
20.3
11.0
5.2
7.9
10.0
5.8
3.1
4.1
2.4
1.4
0.0
0.0
15.1
0.0
1.7
4.1
2.1
1.0
1.0

Notes: TF, transcription factor. TF ChIP-seq peaks are from GSE22178 and E-MTAB3594.
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Figure 5-6. NFIX and PU.1 co-localize and regulate genes associated with cell
adhesion, cell differentiation and cell death.
(A) Signal plot showing the enrichment of PU.1 ChIP peaks center around NFIX. The
antibody used for of each ChIP is shown in parentheses. (B) PANTHER GO terms
associated with genes that are putatively regulated by NFIX and PU.1. (C) Heatmap
showing expression of all genes directly targeted by NFIX and PU.1. (D) Representative
tracks from Nfix+/+ and Nfix-/- samples used for ChIP. The antibody used for ChIP is
indicated as either NFIX or PU.1. Asterisks (*) are placed between PU.1 ChIP tracks
where there was significantly different signal obtained (p = <0.0001).
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GATA2, LYL1, LDB1, RUNX1 and PU.1, were significantly overlapping at promoter
and enhancer regions, suggesting possible co-regulatory functions. We validated colocalization of NFIX with PU.1 in HPC5 cells. Additionally, our work illuminates the
molecular pathways regulated by NFIX and PU.1 in these cells, such as regulating cell
adhesion, cell differentiation and cell death.
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CHAPTER 6.

SUMMARY

Hypothesis and Specific Aims
Our original hypothesis endeavored to better understand the role of Nfix during
steady-state and stress hematopoiesis. We also sought to identify the direct transcriptional
targets of NFIX and what other transcription factors were involved in co-regulating gene
expression.

Nfix Is Dispensable During HSPC Transplant and Steady State Hematopoiesis
It is possible that Nfix is not necessary during hematopoiesis, however, it may also
be that the other Nfi members are compensating for the absence of Nfix. Previously,
androgen receptor (AR) target genes were shown to be influenced by pan-NFI
knockdown [168]. In a prostate cancer cell line, individual NFI gene knockdown was
shown to influence AR target gene expression in a gene-dependent manner [169]. In
general, when NFIB or NFIX were knocked-down AR target genes were repressed.
Conversely, when NFIA or NFIC were knocked down AR target genes were activated.
Also, in these experiments, knockdown of NFIX resulted in increased expression of both
NFIA and NFIB. It will be interesting to evaluate hematopoiesis from double or triple
knockout models to interrogate the necessity of Nfi family members. Indeed, more studies
are needed to understand how this gene family with often overlapping expression
regulates transcription.
The increase in chimerism in the lymphoid compartment could be due to the
absence of NFIX tipping the scales towards that lineage. Indeed, our data agrees with
previous findings that enforced Nfix favors myelopoiesis at the expense of lymphopoiesis
[135]. Our data fit well with O’Connor et al. findings where we also see an increase in
the myeloid lineage when HSPC overexpressing Nfix are transplanted into lethally
irradiated recipients (Figure A-3). Additionally, this same trend has been observed when
expression of NFIA is altered: increased NFIA favors erythroid lineage differentiation
while suppression of NFIA leads to granulopoiesis [115].

Enforced Nfix Promotes Survival of Immature Hematopoietic Cells Ex Vivo
We present work in agreement with other literature in skeletal muscle, where
overexpression of Nfix resulted in exacerbated proliferation of skeletal muscle [119].
Here, we show Nfix promotes differentiation of cultured HSPC towards a mix of
immature progenitors that lack transplantation and CFU potential (Figure A-2 through 5
and 8). This possibly indicates a block in differentiation. It is also possible that Nfix
expression selects for a cell in these cultures that depends on c-MPL signaling for
survival. However, the enhanced survival of NFIX+ cells can also be observed in
immunophenotypic HSPC (Figure A-6), demonstrating that this phenomenon is not
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confined to a particular population. We further demonstrate that NFIX may function as a
transcriptional regulator of c-Mpl. Indeed, NFIX was capable of activating a promoter
containing multiple NFI consensus binding sites located upstream of the c-Mpl promoter.
We also show NFIX-FLAG directly associated with the proximal promoter. NFIX may
also regulate downstream effectors of the TPO/c-MPL signaling pathway, as Stat5a is
significantly upregulated in NFIX+ cells compared to controls (p = 0.0012) (Figure
A-9C). However, this effect may be indirect as there are no NFI consensus binding sites
proximal to the Stat5a promoter (data not shown).
c-Mpl is a well-known regulator of HSPC function, as it is required for the
maintenance of adult quiescent HSCs and protection from DNA-damage induced
apoptosis in vivo [110 170 171]. Our data further implicate Nfix as a novel regulator of
this important HSPC regulatory axis. Further work will be required to determine if Nfixmediated regulation of HSPC responsiveness to TPO contributes to HSPC survival and
niche retention.

Characterization of Genome-Wide Binding of NUCLEAR FACTOR I-X in
Hematopoietic Cells
NFIX is the first NFI member identified as functionally relevant to HSPC biology
in vivo, thus necessitating a more thorough understanding of its function. NFI proteins
have been previously implicated in the regulation of differentiation, proliferation and
survival in many cellular contexts [111-115]. Here, we show that NFIX direct
transcriptional gene targets are enriched for GO terms such as negative regulation of
apoptosis in hematopoietic cells, positive regulation of hematopoietic cell differentiation
and proliferation, positive regulation of adaptive immune response and cell-substrate
adhesion. These data are congruent with earlier findings that Nfix-KO NSC exhibit
increased apoptosis, delayed differentiation and stochastic migration while ectopic Nfix
protects HSPC from apoptosis induced by cytokine-deprivation in vitro. While the exact
mechanism for NFIX regulation of apoptosis is not well understood in hematopoiesis or
neurogenesis, here we identify several target genes (i.e. Il10ra, Irs2, Pdcd1) that are
responsive to external stimuli and anti-apoptotic [172-174]. NFIX also appears to
positively regulate galectin-3 (Lgals3), a lectin family member that associates with antiapoptotic BCL2 [175] and supports mitochondrial integrity during apoptotic stimuli and
stress [176]. The chemokine, CC-chemokine ligand 5 (CCL5), was also positively
regulated by NFIX. CCL5 can have both anti-apoptotic and pro-apoptotic functions [177
178]. Further investigation of the exact mechanisms affected by NFIX will clarify its
precise role in promoting cell survival.
In primary astrocytes, NFIX and STAT3 form a complex to positively regulate
the expression of YKL-40, a migratory factor [179]. In the same study, ectopic
expression of NFIX in glioma cells negatively affected expression of SERPINE1, a
serpin family member. Here, we observed significant co-localization of NFIX and
STAT3 at gene targets in hematopoietic cells, including another serpin family member,
Serpinf1. Serpinf1 encodes pigment epithelium-derived factor (PEDF). PEDF has been
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shown to inhibit the migration of endothelial cells [180] and cancer cell lines [181].
While PEDF is reported as dispensable for HSPC steady-state and regeneration function
[182], there are 60 functional Serpin genes identified in the mouse [183] and 37 in
humans [184]. Thus, PEDF may be readily compensated for by a family member or other
proteinase inhibitors. Whether NFIX and STAT3 together coordinate migration in
hematopoietic cells is an intriguing question. STAT3 has also been implicated a positive
regulator of HSPC regeneration [185]. We had previously implicated NFIX as an
essential factor required for optimal HSPC transplantation [117]. Here, we find colocalization with STAT3 at genes also implicated in hematopoietic reconstitution, such as
Hmga2 [185], Cdkn1c [186] and Clcf1 [187]. Thus, NFIX and STAT3 may cooperate to
promote HSPC reconstitution post-transplant.
We found that NFIX targets genes related to hematopoietic cell differentiation, such
as Meis1. PU.1 induces myeloid lineage commitment in HSPC [188] and directs
progenitors towards the lymphoid lineage [189]. PU.1 is another key hematopoietic
regulator that we found co-localized at gene targets with NFIX. Interestingly, genes
putatively targeted by both NFIX and PU.1 are enriched for GO terms involving cell
proliferation, regulation cell adhesion, cell death and differentiation. Target genes include
Pdcd1, Socs3 and Meis1. NFIX has been shown to modulate HSPC lineage commitment:
enforced NFIX expression skews towards the myeloid lineage at the expense of B cells
[135]. Given the importance of PU.1 across the hematopoietic hierarchy and its colocalization with NFIX, a relatively novel HSPC transcriptional regulator, future studies
should focus on unraveling the relationship between NFIX and PU.1.
Another important consideration is the function of PU.1 as a pioneering factor.
Pioneering factors are proteins that can bind to regions of condensed chromatin and
whose occupancy precedes that of other factors, imparting competency for transcriptional
activity. During hematopoiesis, PU.1 acts as a prototypical pioneer factor as it does not
bind to nucleosomal DNA in vitro. Here we show reduced binding of PU.1 in the absence
of NFIX (Figure 5-6E). Work focused on understanding the binding kinetics between
these two factors will be important in understanding changes in the chromatin landscape
during hematopoiesis. In a prostate cancer cell line, NFIX interacts with FOXA1, another
pioneer factor. However, NFIX represses expression of AR-regulated genes regardless of
FOXA1 [169]. Currently, without ATAC-seq datasets, it is difficult to establish if NFIX
is acting as a pioneer factor in these other cellular contexts. ATAC-seq and ChIP-seq
experiments will be vital in showing how NFIX may function as a pioneer factor.
In summary, ours is the first study to uncover the direct transcriptional targets of
NFIX in hematopoietic cells. These direct targets include genes that regulate apoptosis,
differentiation and cell adhesion. We show NFIX prefers genomic promoters and
enhancers. NFIX also co-localizes with other key hematopoietic transcription factors,
including STAT3, RAD21, pSTAT1, ETO2, FLI1, GATA2, LYL1, LDB1, RUNX1 and
PU.1. We confirmed PU.1 and NFIX genomic co-localization. NFIX appears to be
multifaceted; having roles in binding chromatin boundaries and co-localizing with CTCF,
regulating an anti-apoptotic gene signature, interacting with STAT3 in hematopoietic
cells to promote migration and modulating cell proliferation/differentiation putatively
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with PU.1. Future work towards understanding the role of NFIX with each of these
biological functions will be illuminating, especially its function in the molecular
processes of HSPC transplantation and cooperation with other key hematopoietic factors.
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CHAPTER 7.

FUTURE DIRECTIONS

Importantly, the data presented in this work suggests Nfix has a complex role in
hematopoiesis. Despite the advances reported here, there are still questions that would
further reveal the involvement of Nfix during hematopoiesis.

Do Other NFI Family Members Compensate for the Absence of Nfix During HSCT?
There is evidence of overlapping expression of Nfi family members suggesting
other members may compensate for the loss of another or redundancy. In order to test the
hypothesis that NFI members compensate for the absence of Nfix, performing RNA-seq
on transplanted HSPC from NfixΔ/Δ mice would be illuminating. RNA-seq has the
advantage over qRT-PCR by being more sensitive and providing substantially more data.
In addition to being able to determine the quantity of transcripts of other NFI family
members, one could perform differential gene expression analysis and use this list of
genes to assign GO terms. This differs from our current data as our data was collected
without transplantation or any other form of stress.

Is the NFI Family Dispensable for Hematopoiesis?
Our lab and others have implicated the NFI family in hematopoiesis. Most of
these studies have involved cell lines, in vitro analyses and single KO mouse models. I
propose that working with a triple KO or double KO mouse models would be the most
rigorous way to test this hypothesis. Nfic-/- mice are viable and require soft chow. We
currently have the Nfixflox/flox mouse model and an Nfiaflox/flox mouse model exists,
although would need to be backcrossed onto a C57Bl6/J background. Breeding strategies
to generate an Nfic-/- Nfixflox/flox Nfiaflox/flox HSC-Scl-Cre-ERT mouse model would allow
for fairly normal development (i.e. the mice would need to be fed soft chow as the Nfic-/mice have defective molar root formation). Thus, the two floxed genes could be spatially
and temporally deleted in HSPC and transplanted into lethally irradiated recipient mice.
Controls would lack the HSC-Scl-Cre-ERT knockin allele but still be treated with
Tamoxifen.
In the same way, one could imagine having double KO models to interrogate if a
specific NFI family member is required for hematopoiesis (i.e. Nfic-/- Nfixflox/flox HSC-SclCre-ERT or Nfic-/- Nfiaflox/flox HSC-Scl-Cre-ERT). We have not found evidence for the
expression of Nfib in the hematopoietic hierarchy (data not shown).

How Does NFIX Regulate the Globin Genes?
Recently, NFIX was implicated as a repressor of fetal hemoglobin (HbF) [190].
Briefly, during development there is a developmentally regulated switch from the
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expression of HbF to adult hemoglobin. To better understand which transcription factors
may be involved in this switching Chaand et al. used ATAC-seq and transcriptionally
profiled differentiated CD34+ cells from adult BM, CD34+ cells from cord blood (CB)
and HUDEP-2 cells, an immortalized human erythroid progenitor cell line. Their results
show the NFI motif was enriched in regions of chromatin accessibility in cells from adult
BM compared to cells from CB. more differentiated HUDEP-2 cells compared to a less
differentiated stage. They also show an increase in NFIX mRNA in adult BM compared
to CB. These data suggest NFIX plays a role in repressing HbF during the developmental
switch to adult hemoglobin. To test this hypothesis Chaand et al. knocked-down NFIX in
CD34+ cells from adult BM and HUDEP-2 cells. This caused an increase in HbF
comparable to when BCL11A, a known HbF repressor, is knocked-down. Together, their
data strongly implies that NFIX represses HbF during development. This has implications
in treating diseases where an increase in HbF would have therapeutic impact, such as
with sickle cell anemia. Regulation of the globin gene locus is very complex and has
limited the ability of researchers to fully understand how it is regulated. Performing
ChIP-seq using HUDEP-2 cells or CD34+ cells from adult BM and CB may offer more
insight into how this important cluster of genes is regulated, especially in combination
with Chaand et al. ATAC-seq data and using their shRNAs as a control.

Does NFIX Require PU.1 Binding First or Does NFIX Function as a Pioneering
Factor?
We have data suggesting NFIX and PU.1, a master transcription factor, colocalize regions of the HPC5 cell genome. There is an obvious question about which
factor binds first? To better understand the answer to this question, one could imagine
knocking down PU.1 and then perform ChIP with our anti-NFIX antibody to test if NFIX
binding is still present or reduced. Also, there is a competitive PU.1 inhibitor (PU.1-ets)
that encodes only the DNA binding domain of PU.1. PU.1 requires it’s protein-protein
interaction domains in order to bind DNA and affect transcription.
Pioneering factors are transcription factors that can bind to regions of condensed
chromatin and whose occupancy precedes that of other factors, imparting competency for
transcriptional activity. Pioneering factors are especially important during development
and lineage determination. It will be advantageous to use a cellular model where
differentiation in vitro is possible to track the presence of NFIX at different regulatory
enhancers and promoters. For example, previous work has used a skeletal muscle cell line
to study the role of NFIX when differentiating embryonic myoblasts to fetal myoblasts
[118]. In these studies, there is a clear role for NFIX regulating differentially expressed
genes between the two developmental stages; however, use of our anti-NFIX antibody
would determine if NFIX is affecting condensed regions of chromatin and “priming”
these areas for other transcription factor occupancy. Additionally, the NFI members have
established roles in NSC development. It will be informative to test the occupancy of
NFIX throughout hierarchies of development (e.g. hematopoiesis, NSC development).
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What Other Proteins Interact With NFIX?
Immunoprecipitation followed by mass spectrophotometry (IP-MS) relies on
protein abundance as well as a robust, specific antibody for the protein on interest. With
our novel antibody, we can globally interrogate what other proteins are physically
interacting with NFIX. Furthermore, editing of NFI domains followed by IP-MS may be
informative towards understanding what domains of NFIX are important for proteinprotein interactions. The caveat here is to make certain the anti-NFIX antibody is still
useable/specific when NFIX has been modified/truncated.
We show there is overlapping signal between NFIX and CTCF in HPC5 cells.
The NFI proteins have been known to re-shape DNA, remodel chromatin and bind
chromatin boundaries. To determine how NFIX and CTCF interact, it would be worth
performing HiChIP. HiChIP combines ChIP with chromosome conformation capture
coupled with high-throughput sequencing. Using our anti-NFIX antibody, we could
perform HiChIP to interrogate long range interaction by NFIX. Including the Nifx-/HPC5 cells would further inform if NFIX is necessary for CTCF binding or if NFIX
functions as a transcriptional insulator.
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APPENDIX A. SUPPLEMENTAL DATA FOR CHAPTER 4

Figure A-1. NFIX overexpression promotes accelerated differentiation of LSK
cells during ex vivo culture.
(A) FACS plots depicting the sorting schematic for freshly isolated LSK cells. (B) LSK
immunophenotype of control and NFIX+ cells at day 0, 7, and 14 of culture depicted a
representative dot plot from three independent experiments. (C) LSK immunophenotype
of control and NFIX+ cells at day 14 of culture depicted as bar plot (n = 3). (D) One-way
FACS histogram depicting a reduction in c-KIT+ cells among the lineage negative
population of control and NFIX+ cells after seven days of ex vivo culture. All values
represent mean ± standard deviation. NS denotes not significant.
Reprinted with permission from John Wiley and Sons. Hall, T.*, Walker, M.*, Ganuza,
M., Holmfeldt, P., Bordas, M., Kang, G., Bi, W., Palmer, L.E., Finkelstein, D. and
McKinney‐Freeman, S. (2018), Nfix Promotes Survival of Immature Hematopoietic Cells
via Regulation of c‐Mpl . Stem Cells, 36: 943-950. (*Co-first author). doi:
http://dx.doi.org/10.1002/stem.2800.
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Figure A-2. HSPC overexpressing Nfix display an immature blast-like
morphology similar to control cells.
Romanowsky stain of fresh bone marrow (BM) LSK (HSPC), culture day seven (D7)
GFP+ MND-Control, D7 GFP+ NFIX+ cells, and day thirty (D30) GFP+ NFIX+ cells.
Representative images from two independent experiments are shown.
Reprinted with permission from John Wiley and Sons. Hall, T.*, Walker, M.*, Ganuza,
M., Holmfeldt, P., Bordas, M., Kang, G., Bi, W., Palmer, L.E., Finkelstein, D. and
McKinney‐Freeman, S. (2018), Nfix Promotes Survival of Immature Hematopoietic Cells
via Regulation of c‐Mpl . Stem Cells, 36: 943-950. (*Co-first author). doi:
http://dx.doi.org/10.1002/stem.2800.
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Figure A-3. HSPCs overexpressing Nfix fail to repopulate the bone marrow of
irradiated recipients and display a myeloid bias in lineage distribution.
(A) Schematic displaying competitive transplantation assay to assess hematopoietic
repopulation potential of HSPC. CD45.2 “test” LSK cells were harvested from bone
marrow and transduced with either MND-control or MND-Nfix lentiviral vectors.
CD45.1 “competitor” LSK cells were mock transduced. 24 hours post-transduction, 5000
test and 5000 competitor cells were harvested and transplanted into irradiated recipients.
(B) Percentage of CD45.2 “test” cells in the peripheral blood of transplanted recipients
over a 16 week period. (C) Percentage of GFP+ cells within CD45.2 “test” cells in the
peripheral blood of transplanted recipients over a 16 week period. (D) Percentage of T-,
B-, and myeloid cells within CD45.2 “test” cells in the peripheral blood of transplanted
recipients over a 16 week period.
Reprinted with permission from John Wiley and Sons. Hall, T.*, Walker, M.*, Ganuza,
M., Holmfeldt, P., Bordas, M., Kang, G., Bi, W., Palmer, L.E., Finkelstein, D. and
McKinney‐Freeman, S. (2018), Nfix Promotes Survival of Immature Hematopoietic Cells
via Regulation of c‐Mpl . Stem Cells, 36: 943-950. (*Co-first author). doi:
http://dx.doi.org/10.1002/stem.2800.
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Figure A-4. HSPC overexpressing Nfix display reduced CFU potential.
(A) Frequency of colony-forming units among GFP+ control and NFIX+ cells cultured
for seven days ex vivo (n = 3). (B) Frequency of colony-forming units among GFP+
control and NFIX+ cells cultured for 21 days ex vivo (n = 3). The frequency of colony
forming units refers to the number of colonies scored divided by the total number of cells
plated in methylcelluose. All values represent mean ± standard deviation. NS denotes not
significant.
Reprinted with permission from John Wiley and Sons. Hall, T.*, Walker, M.*, Ganuza,
M., Holmfeldt, P., Bordas, M., Kang, G., Bi, W., Palmer, L.E., Finkelstein, D. and
McKinney‐Freeman, S. (2018), Nfix Promotes Survival of Immature Hematopoietic Cells
via Regulation of c‐Mpl . Stem Cells, 36: 943-950. (*Co-first author). doi:
http://dx.doi.org/10.1002/stem.2800.
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Figure A-5. Nfix-overexpressing cells display no major lineage markers and an
immature progenitor immuno-phenotype.
(A) Percentage of lineage+ cells among GFP+ control and NFIX+ cells as one (n = 3),
three (n = 2), and four (n = 3) weeks in ex vivo culture. (B) Percentage of c-Kit+ CD71+
cells among GFP+ control and NFIX+ cells at various time-points during ex vivo culture.
(C) Representative FACS plot depicting the percentage of CD71hi cells in GFP+ control
and NFIX+ cultures at day seven and day 30 of ex vivo culture. All values represent
mean ± standard deviation. Note: all comparisons in (A) are not significant.
Reprinted with permission from John Wiley and Sons. Hall, T.*, Walker, M.*, Ganuza,
M., Holmfeldt, P., Bordas, M., Kang, G., Bi, W., Palmer, L.E., Finkelstein, D. and
McKinney‐Freeman, S. (2018), Nfix Promotes Survival of Immature Hematopoietic Cells
via Regulation of c‐Mpl . Stem Cells, 36: 943-950. (*Co-first author). doi:
http://dx.doi.org/10.1002/stem.2800.
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Figure A-6. LSK cells overexpressing Nfix display reduced apoptosis under
cytokine deprivation during ex vivo culture.
Percentage of GFP+ apoptotic cells within control or NFIX+ LSK cells at day seven of ex
vivo culture (n = 3). All values represent mean ± standard deviation. NS denotes not
significant.
Reprinted with permission from John Wiley and Sons. Hall, T.*, Walker, M.*, Ganuza,
M., Holmfeldt, P., Bordas, M., Kang, G., Bi, W., Palmer, L.E., Finkelstein, D. and
McKinney‐Freeman, S. (2018), Nfix Promotes Survival of Immature Hematopoietic Cells
via Regulation of c‐Mpl . Stem Cells, 36: 943-950. (*Co-first author). doi:
http://dx.doi.org/10.1002/stem.2800.
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Figure A-7. Nfix overexpression affects the expression of other known regulators
of HSPC biology.
Relative expression of several regulators of HSPC biology in NFIX+ cells compared to
control cells known to be down-regulated upon shRNA-induced Nfix knockdown [10] at
day seven of ex vivo culture (n = 3). All values represent mean ± standard deviation. NS
denotes not significant.
Reprinted with permission from John Wiley and Sons. Hall, T.*, Walker, M.*, Ganuza,
M., Holmfeldt, P., Bordas, M., Kang, G., Bi, W., Palmer, L.E., Finkelstein, D. and
McKinney‐Freeman, S. (2018), Nfix Promotes Survival of Immature Hematopoietic Cells
via Regulation of c‐Mpl . Stem Cells, 36: 943-950. (*Co-first author). doi:
http://dx.doi.org/10.1002/stem.2800.
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Figure A-8. HSPCs overexpressing Nfix are not enriched for megakaryocyte
progenitors or CFU-Megs.
(A) Frequency of GFP+ CFU-Megs from control day seven, NFIX+ day seven, and
NFIX+ day 30 ex vivo cells (n = 2). (B) Representative images of CFU-Megs from
control day seven, NFIX+ day seven, and NFIX+ day 30 ex vivo cells (n = 2). (C)
Percentage of megakaryocyte progenitors
(c-Kit+Sca-1-CD127-CD9+CD32/CD16loCD41+) among GFP+ control and GFP+
NFIX+ cells (n = 4). All values represent mean ± standard deviation.
Reprinted with permission from John Wiley and Sons. Hall, T.*, Walker, M.*, Ganuza,
M., Holmfeldt, P., Bordas, M., Kang, G., Bi, W., Palmer, L.E., Finkelstein, D. and
McKinney‐Freeman, S. (2018), Nfix Promotes Survival of Immature Hematopoietic Cells
via Regulation of c‐Mpl . Stem Cells, 36: 943-950. (*Co-first author). doi:
http://dx.doi.org/10.1002/stem.2800.
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Figure A-9. NFIX+ cells display enhanced TPO/c-MPL signaling sensitivity to
mTPO exposure.
(A) Relative phosphorylation status of STAT5, AKT, and ERK1/2 in NFIX+ cells during
a time-course of mTPO exposure following cytokine starvation, as measured by
phosphoflow (STAT5, ERK1/2: n = 4; AKT: n = 3). gMFI: Geometric mean fluorescence
intensity. (B) Relative expression of Bcl-xL in NFIX+ cells compared to control cells at
different time points during ex vivo culture, quantified by qRT-PCR (n = 3). Tbp was
used as a housekeeping gene. (C) Relative expression of Stat5a and Stat5b in NFIX+
cells compared to control cells at day seven of ex vivo culture, quantified by qRT-PCR (n
= 6). Tbp was used as a housekeeping gene. All values represent mean ± standard
deviation. NS denotes not significant.
Reprinted with permission from John Wiley and Sons. Hall, T.*, Walker, M.*, Ganuza,
M., Holmfeldt, P., Bordas, M., Kang, G., Bi, W., Palmer, L.E., Finkelstein, D. and
McKinney‐Freeman, S. (2018), Nfix Promotes Survival of Immature Hematopoietic Cells
via Regulation of c‐Mpl . Stem Cells, 36: 943-950. (*Co-first author). doi:
http://dx.doi.org/10.1002/stem.2800.
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APPENDIX B. SUPPLEMENTAL DATA FOR CHAPTER 5

Figure B-1. mAb 7B5.3 specifically detects murine NFIX.
(A) Alignment of the four characterized NFIX protein isoforms. The underlined portion
is the 3’ end of the DNA binding domain. The red font, downstream of the DNA binding
domain, is the sequence used to generate a peptide for antibody production and is
conserved between the four NFIX isoforms. (B) Western blot showing
immunoprecipitation from 293T cells lysates overexpressing FLAG-NFIX or FLAGNFIA. Expected size of FLAG-NFIX: 50kDa. Expected size of FLAG-NFIA: 55kDa.
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Figure B-2. NFIX expression in Nfix+/+ and Nfix-/- HPC5 cells.
(A) Red font indicates guide RNA (gRNA) designed for CRISPR-Cas9 editing. Top row
shows wild-type Nfix sequence and bottom rows show deep sequencing results of edited
Nfix-/- alleles from clonal cell line. (C) Real-time polymerase chain reaction results show
expression of Nfix, Nfic, Nfia and c-Mpl. Tata binding protein (Tbp) was used for
normalization. n=3.
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Table B-1.
Gene set enrichment analysis of differentially expressed genes in
-/Nfix HPC5 cells compared to Nfix+/+ HPC5 cells.
Name
GSE21360_SECONDARY_VS_QUATER
NARY_MEMORY_CD8_TCELL_DN
LEONARD_HYPOXIA
HALLMARK_HYPOXIA
HALLMARK_TNFA_SIGNALING_VIA_
NFKB
HESS_TARGETS_OF_HOXA9_AND_ME
IS1_DN
MCLACHLAN_DENTAL_CARIES_UP
ELVIDGE_HYPOXIA_BY_DMOG_UP
ELVIDGE_HIF1A_AND_HIF2A_TARGE
TS_DN
ELVIDGE_HIF1A_TARGETS_DN
FARDIN_HYPOXIA_11
QI_HYPOXIA
MARKEY_RB1_ACUTE_LOF_UP
ROSS_AML_WITH_CBFB_MYH11_FUS
ION
GSE34156_TLR1_TLR2_LIGAND_VS_N
OD2_AND_TLR1_TLR2_LIGAND_24H_
TREATED_MONOCYTE_UP
JAATINEN_HEMATOPOIETIC_STEM_C
ELL_DN
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Size

ES

NES

144

-0.7341201

-2.419984

42
157

-0.8566726
-0.7113717

-2.3905966
-2.3839848

167

-0.6965964

-2.3609939

68

-0.7889371

-2.3598282

157
100

-0.69516593
-0.7258216

-2.340464
-2.3357708

74

-0.77127725

-2.326851

64
29
119
180

-0.7779772
-0.8863163
-0.7085281
-0.67329854

-2.3259497
-2.321957
-2.284275
-2.2832403

43

-0.8033612

-2.2684298

148

-0.6741672

-2.254935

146

-0.67163336

-2.2485745

Figure B-3. Sfpi1 expression in Nfix-/- HPC5 cells.
(A) Log2 transcript per million (TPM) for Sfpi1 in Nfix+/+ HPC5 cells and Nfix-/- HPC5
cells. These values are from the RNA-seq dataset described in Chapter 5 (n=3).
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